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1 Introduction 
1.1 Hepatitis C virus (HCV) infection 
HCV was first isolated in 1989 (Choo et al., 1989) after its existence had first been 
postulated 15 years earlier to explain the occurrence of transfusion-associated liver 
disease in individuals infected with neither the hepatitis A or B viruses (Alter et al., 
1975; Feinstone et al., 1975; Prince et al., 1974). According to the World Health 
Organization (WHO) approximately 130-150 million people worldwide are currently 
infected with HCV and 3-4 million new infections occur every year causing both acute 
and chronic liver infection (WHO, 2014). Acute infection remains asymptomatic in the 
vast majority of cases and 15-45% of patients are able to spontaneously clear the 
infection within 6 months. The 55-85% of patients who develop chronic infection have 
a great risk of developing liver fibrosis, cirrhosis or hepatocellular carcinoma (HCC). 
Progression of liver disease occurs over several decades and 10-20% of patients 
develop cirrhosis over 20–30 years of infection (Esteban et al., 2008). In cirrhotic 
patients the risk of developing HCC is approximately 1-5% per year and patients 
diagnosed with HCC have a 33% probability of death during the first year after 
diagnosis (Afdhal, 2004; Fattovich et al., 1997; Mutimer et al., 2014; Poynard et al., 
1997; Thein et al., 2008).  
If symptoms occur during the acute phase of infection they are usually mild and 
unspecific like fatigue, myalgia, low-grade fever, nausea and vomiting, even though 
jaundice is also observed (WHO, 2014). Interestingly, asymptomatic infection results 
in the establishment of a chronic infection in 85-90% of cases, whereas spontaneous 
viral clearance is more frequently observed in patients with jaundice and other severe 
clinical signs of hepatitis (Gerlach et al., 2003). The presence of jaundice might be an 
indicator for a successful host immune response by cytotoxic cells that results in 
clearance of the virus.  
 
1.2 HCV and its genome organisation 
HCV is a member of the Flaviviridae family, which also includes yellow fever and 
dengue, and is the prototype virus in the Hepacivirus genus (Moradpour et al., 2007), 
which now also includes the GB-virus B and the recently identified nonprimate, 
rodent and bat hepaciviruses (NPHV (Kapoor et al., 2011), RHV (Kapoor et al., 2013) 
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and BHV (Quan et al., 2013)). It has a 9.6 kb large positive-strand ribonucleic acid 
(RNA) genome, which contains 5’ and 3’ untranslated regions (UTRs) flanking a 
single open reading frame (ORF) of approximately 3000 amino acids (aa) (figure 1.1) 
(Bartenschlager et al., 1993). The 5’ UTR is a highly conserved region and contains 
four different domains. Domains II-IV together with the first 24-40 nucleotides of the 
core coding region constitute the internal ribosomal entry site (IRES), which mediates 
the translation of the ORF (Otto and Puglisi, 2004; Tsukiyama-Kohara et al., 1992). 
Translation of the viral genome gives rise to a polyprotein that is cleaved by viral and 
host proteases into 10 viral proteins: the structural proteins core, E1 and E2, and the 
non-structural proteins p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B. 
The 3’ UTR located downstream of the coding region is composed of a short variable 
region, a poly(U/UC) tract with an average length of 80 nucleotides and an RNA 
element called the X-tail, which is almost invariant. The conserved elements in the 3’ 
UTR are essential for HCV replication (Kolykhalov et al., 1996; Tanaka et al., 1996; 
Yanagi et al., 1999). 
 
 
Figure 1.1: HCV genome organisation and polyprotein processing 
The HCV genome contains one ORF flanked by 5’ and 3’ UTRs (top). IRES-mediated translation 
yields a polyprotein that is further co- and post-translationally cleaved by host and viral proteases as 
indicated (triangles). Glycosylation of the envelope proteins (black dots) and the functions of the 
individual HCV proteins are indicated. Modified from (Moradpour et al., 2007; Scheel and Rice, 2013). 
 
5’ UTR 
3’ UTR 
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1.3 HCV viral life cycle 
1.3.1 Entry and uncoating 
Entry of HCV into hepatocytes is a multistep process requiring the viral envelope 
glycoproteins as well as several cellular attachment and entry factors (figure 1.2 a 
and b).  
 
 
 
Figure 1.2: HCV viral life cycle 
Virus binding and internalization (a); cytoplasmic release and uncoating (b); IRES-mediated 
translation and polyprotein processing (c); RNA replication (d); packaging and assembly (e); virion 
maturation and release (f). The topology of HCV structural and non-structural proteins at the 
endoplasmic reticulum (ER) membrane is shown schematically. Modified from (Moradpour et al., 
2007). 
 
Initial low affinity cell binding has been attributed to the low-density lipoprotein (LDL) 
receptor and glycosaminoglycans (GAG) (Agnello et al., 1999; Barth et al., 2003), 
followed by E1-E2 interaction with the co-receptors scavenger receptor class B type I 
(SR-BI) (Scarselli et al., 2002) and the tetraspanin cluster of differentiation (CD) 81 
(Pileri et al., 1998). In addition, the tight-junction proteins claudin-1 (CLDN1) (Evans 
et al., 2007) and occludin (OCLN) (Ploss et al., 2009) as well as the receptor tyrosine 
kinases epidermal growth factor receptor (EGFR) and ephrin receptor type A2 
(EphA2), which have both been associated with the possible modulation of the 
interactions between CD81 and CLDN1 (Lupberger et al., 2011), are required for 
entry. Virion-associated cholestrol seems to be involved at a late stage of HCV entry 
by interacting with the Niemann-Pick C1–like 1 (NPC1L1) cholesterol absorption 
Introduction 
 
 4 
receptor (Sainz et al., 2012). Internalization occurs via clathrin-mediated endocytosis 
(Blanchard et al., 2006) followed by pH-dependent membrane fusion within an acidic 
endosomal compartment leading to the release of the HCV genome into the 
cytoplasm (Koutsoudakis et al., 2006; Tscherne et al., 2006). Fusion is probably 
mediated by E2, which is a predicted class II fusion protein (Krey et al., 2010) and 
has been shown to be primed for activation at acidic pH levels (Sharma et al., 2011). 
 
1.3.2 Translation and polyprotein processing 
Translation in association with the ER is initiated by the formation of a binary 
complex between the IRES and the 40S ribosomal subunit followed by the assembly 
of a 48S-like complex at the AUG initiation codon after the association of eukaryotic 
translation initiation factor 3 (eIF3) and the ternary complex (eIF2•Met-tRNAi•GTP) 
(figure 1.2c). The 60S subunit is then associated in a GTP-dependent manner to 
form the 80S complex (Otto and Puglisi, 2004). The resulting polyprotein precursor is 
co- and post-translationally processed. While the structural proteins and the p7 
polypeptide are cleaved by cellular proteases (signalase and signal peptide 
peptidase, indicated by white and grey triangles in figure 1.1), the non-structural 
proteins are processed by the two viral proteases NS2-3 protease and NS3-4A 
serine protease (indicated by red and green triangles in figure 1.1) (Scheel and Rice, 
2013). 
 
1.3.3 RNA replication 
NS4B and NS5A induce the formation of ER-derived membrane spherules, which in 
aggregate are called the membranous web. This structure is believed to be the site of 
HCV RNA replication (Egger et al., 2002; Romero-Brey et al., 2012). Three viral 
proteins are thought to be involved in RNA replication. The NS3 protein is capable of 
nucleic-acid binding and 3’ to 5’ translocation coupled to hydrolysis of ATP, as it 
contains a superfamiliy 2 DExH/D-box helicase domain (Raney et al., 2010). This 
helicase activity could be important for separation of the nascent and template RNA 
strands, displacement of RNA-binding proteins or unwinding of local RNA secondary 
structures. NS5A is a phosphoprotein that consists of three domains. While domains 
I and II are essential for RNA replication (Tellinghuisen et al., 2004, 2008a), domain 
III plays a role in virus assembly (Appel et al., 2008; Tellinghuisen et al., 2008b). The 
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phosphorylation state of NS5A determines the regulation of the balance between 
RNA replication and downstream processes (Neddermann et al., 2004). The most 
important viral protein for RNA replication is the RNA-dependent RNA polymerase 
(RdRp) NS5B. This protein facilitates replication by first synthesising a 
complementary negative-strand RNA using the genome as a template and 
subsequently producing a genomic positive-strand RNA from the negative-strand 
template (figure 1.2d) 
 
1.3.4 Virus assembly and release 
Virus assembly and release is tightly regulated and coupled to host cell lipid 
synthesis (Scheel and Rice, 2013). After processing of the core protein by host cell 
proteases, the mature protein relocates from the ER membrane to cytoplasmic lipid 
droplets (cLDs) (Boulant et al., 2006; McLauchlan et al., 2002). This process is 
facilitated by diacylglycerol acyltransferase-1 (DGAT-1) (Herker et al., 2010). The 
complete process of nucleocapsid formation has not been fully elucidated yet, but the 
current model proposes an interaction of core with NS5A either on cLDs or after 
translocation from the mobile cLDs to the ER (Appel et al., 2008; Miyanari et al., 
2007; Shavinskaya et al., 2007). Delivery of HCV genomic RNA to the site of 
nucleocapsid formation is probably achieved via the close proximity of sites of RNA 
replication and virion assembly and via NS2-coordinated virion assembly through 
interactions with glycoproteins, p7, NS3 and NS5A (Jirasko et al., 2010; Popescu et 
al., 2011). p7 oligomers are believed to form ion channels that prevent the 
acidification of intracellular compartments and thereby virus inactivation during the 
release of the viral particle (Wozniak et al., 2010). The E1 and E2 glycoproteins are 
translocated from the ER by a series of signal and stop-transfer sequences, thereby 
giving them a type I membrane protein topology. The E1-E2 glycans are 
subsequently folded, assembled into heterodimers and N-linked sugars are added, 
before they are trimmed by glycosidases I and II (figure 1.2e and f) (Lavie et al., 
2007).  
 
1.4 Therapy 
The primary goal of HCV therapy is to cure the infection. A sustained virological 
response (SVR) is defined as undetectable HCV RNA either 12 weeks (SVR12) or 24 
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weeks (SVR24) after treatment completion. Until 2011, a combination of pegylated 
IFN-α and ribavirin was administered for 24-48 weeks to treat HCV infection (Craxì et 
al., 2011). With this treatment SVR rates of about 40-50% could be achieved in 
patients infected with genotype 1, while considerably higher SVR rates of up to 80% 
were achieved in patients infected with genotypes 2, 3, 5, and 6. Intermediate SVR 
rates were observed in genotype 4 infected patients (Antaki et al., 2010). In 2011, the 
first wave of first-generation direct-acting antivirals (DAAs) was approved for 
treatment of HCV genotype 1 infection. Telaprevir and boceprevir are both protease 
inhibitors, as they target the NS3/4A serine protease. Both drugs must be 
administered in combination with pegylated interferon (IFN)-α and ribavirin. In phase 
III trials of these triple drug combinations, SVR rates of 65-75% were achieved, but 
severe side-effects were still observed (Bacon et al., 2011; Jacobson et al., 2011; 
Poordad et al., 2011; Zeuzem et al., 2011).  
Three new DAAs will be licensed in the European Union in the first half of 2014 for 
use in combination therapies (Pawlotsky, 2014). Sofosbuvir is a nucleotide analogue 
inhibitor of the RdRp and has been approved in January 2014. Simperevir is a 
second-wave first-generation protease inhibitor, which has been approved in May 
2014. Daclatasvir is an NS5A inhibitor that will probably be approved in August or 
September 2014 (Pawlotsky, 2014). All of these show an improved efficacy and 
tolerability compared to telaprevir and boceprevir (Au and Pockros, 2014). 
 
1.5 HCV genotypes and distribution 
HCV has a very high replication rate of an estimated 1012 virions per day per person 
(Neumann et al., 1998). Due to the lack of proofreading activity the RdRp has a high 
error rate that leads to approximately 104 to 105 nucleotide exchanges per generation 
(Drake et al., 1998; Holland et al., 1982). Taken together, this results in the 
generation of approximately 109 viral variants in each infected patient several times 
per day (Guedj et al., 2010). These viral variants are closely related, but still distinct 
and are termed the viral quasispecies. Viruses within the same quasispecies show 
91-99% similarity in conserved genomic regions, but are distinguishable in the more 
variable regions such as hypervariable region-1 (HVR-1) and HVR-2. The high 
variability of HCV facilitates the adaptation to changes in the replication environment 
like selection pressure imposed by drugs or by the host immune response. Beyond 
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this sequence diversity within the quasispecies, more substantial differences exist 
between HCV variants at the population level. 
HCV is grouped into seven different genotypes (1-7) with about 30% sequence 
divergence and multiple subtypes (a,b,c,…) with about 15-20% sequence divergence 
(Gottwein and Bukh, 2008; Smith et al., 2014). The geographic distribution of these 
genotypes is quite distinct, with genotype 1 being the most common genotype in 
America (70%), Japan (75%) and Europe (50-75%). Genotypes 2 and 3 are also 
common in these areas, while genotypes 4 and 5 are common in Africa, but are also 
spreading to Europe. Genotypes 3 and 6 are prevalent in South and Southeast Asia. 
Genotype 7 has recently been isolated from a few patients in Central Africa, but does 
not have widespread clinical importance yet (Scheel and Rice, 2013). 
Genotype distribution does not only differ according to geographical location, but also 
by transmission route. In Europe infections resulting from infected blood transfusions 
are predominantly associated with genotype 1b infection, while genotype 1a and 3a 
are frequently observed in people who inject drugs (PWID) (Esteban et al., 2008). 
  
1.6 Transmission of HCV 
HCV is mainly transmitted via exposure to infectious blood or blood products. In the 
past before the introduction of serological and molecular diagnostic tests, the main 
risk factor for acquiring HCV was transfusion of blood products. In the late 1980s 
2-10% of blood products in developed countries contained HCV (Alter et al., 1981; 
Colombo et al.; Esteban et al., 1990; Prati, 2006) leading to the infection of most 
chronic transfusion recipients and patients receiving clotting factor concentrates 
(Esteban et al., 1989; Mannucci and Tuddenham, 2001; Prati, 2000, 2002). 
Nowadays, blood products in Europe are very safe and no HCV infections due to the 
administration of plasma-derived products have been reported since 1994 (Prati, 
2006). Nevertheless, blood products remain the major cause of HCV transmission in 
developing countries without routine HCV diagnostic tests. In developed countries 
like Germany injection drug use (IDU) has become the main risk factor for HCV 
infection (Aceijas and Rhodes, 2007; Cornberg et al., 2011; Nelson et al., 2011).  
 
1.7 HCV infection in PWID 
Due to their risk behavior of sharing needles and other injection equipment and the 
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resulting blood-to-blood contact, PWID have become the main risk group for HCV 
infection. Worldwide an estimated 16 million PWID existed in 2007 (Mathers et al., 
2008), while according to the European Monitoring Center for Drugs and Drug 
Addiction (EMCDDA) and Eurosurveillance an estimated 1.7 million PWID exist in 
European countries (Esteban et al., 2008; Wiessing, 2005). 
 
 
Figure 1.3: Prevalence of HCV antibodies in PWID 
Prevalence of anti-HCV antibodies was determined in PWID and used as a marker for contact to HCV. 
Modified from (Nelson et al., 2011). 
 
Prevalence of HCV infection in PWID ranges widely (figure 1.3), but accounts for 
60-80% of prevalent infections in North America and most European countries 
(Dalgard et al., 2003; Harris et al., 1999; Hutchinson et al., 2006; Nelson et al., 2011; 
Sutton et al., 2006; Westin et al., 1999). As IDU is a very efficient route of HCV 
transmission, PWID are rapidly infected after they begin IDU. Factors including age, 
duration and frequency of IDU, sharing equipment, polydrug use, HCV prevalence 
among experienced PWID, homelessness and having served a prison sentence also 
play a role in the swift transmission of HCV in PWID (Garfein et al., 1998; Hagan et 
al., 2001; Hickman et al., 2007; Judd et al., 2005; Mathei et al., 2006; Villano et al., 
1997).  
PWID are frequently exposed to different HCV genotypes due to the heterogeneous 
genotype distribution within this group. Evidence for this can also be found in the 
existence of intergenotypic HCV recombinants (genotype 1b/2k) in PWID that are 
rapidly spreading (Kalinina et al., 2002; Moreau et al., 2006). Previous clearance of 
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HCV infection does not provide sterilizing immunity upon renewed antigen exposure 
(Aberle et al., 2006; Aitken et al., 2008; Grebely et al., 2006; Mehta et al., 2002; 
Micallef et al., 2007; Mizukoshi et al., 2008). However, resolved HCV infection is at 
least associated with partial protection, as the incidence of reinfection is low 
compared to acquisition of primary HCV infections (Aberle et al., 2006; Mehta et al., 
2002; Mizukoshi et al., 2008; Osburn et al., 2010). 
In Germany, a recent epidemiological study of PWID revealed that 45.2% of PWID 
were HCV-RNA positive indicating acute or chronic infection, another 27.9% were 
anti-HCV positive but HCV-RNA negative consistent with resolved HCV infection, 
while the remaining 26.9% of PWID were anti-HCV negative although the reported 
risk behavior suggests that they have been exposed to the HCV (Zimmermann, 
2012). 
 
1.8 Immune response against HCV 
Both the innate and adaptive arms of the immune response play an important role in 
the control of HCV infection. During HCV replication the virus is identified as nonself 
by pattern recognition receptors (PRRs) in the host cell that bind pathogen-
associated molecular patterns (PAMPs) within viral products. This PAMP recognition 
leads to a coordinated activation of the innate and adaptive immune responses. 
 
1.8.1 Innate immune response 
The first response during HCV infection is thought to be IFN-β production by infected 
hepatocytes and plasmacytoid dendritic cells (pDCs). This response is initiated by 
three PRRs: retinoic acid-inducible gene-I (RIG-I), protein kinase R (PKR) and Toll-
like receptor 3 (TLR3).  
RIG-I recognizes the HCV 3’ poly (U/UC) sequence, the 5’ triphosphate of the 
uncapped HCV RNA and short double-stranded (ds) RNA regions (Saito et al., 2008; 
Uzri and Gehrke, 2009). These HCV PAMPs could be recognized by RIG-I either 
after viral uncoating when the HCV genome is present in the cytosol or during 
genome amplification.  Binding of HCV RNA to RIG-I induces a conformational 
change that results in oligomerization and translocation from the cytosol to 
intracellular membranes, where it ultimately interacts with the mitochondrial antiviral 
signalling protein (MAVS) (Jiang et al., 2011; Liu et al., 2012; Saito et al., 2007).  
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The kinase activity of PKR can be activated by binding to the IRES of HCV (Shimoike 
et al., 2009) and leads to the phosphorylation of the α subunit of eIF2. In addition, 
PKR binding of HCV RNA also activates a kinase-independent signal transduction 
cascade also involving MAVS (McAllister and Samuel, 2009). 
TLR3 senses dsRNA replication intermediates that accumulate late during HCV 
replication in endosomes and is expressed in a number of intrahepatic cell types 
such as hepatocytes and the liver-resident macrophages Kupffer cells (Li et al., 2012; 
Seki and Brenner, 2008; Wang et al., 2009). Upon ligand binding, TLR3 transmits 
signals through the adaptor protein Toll/interleukin (IL)-1 receptor (TIR)-domain-
containing adaptor-inducing IFN-β (TRIF) (Takeuchi and Akira, 2009). 
The activation of both MAVS and TRIF induces a complex assembly of different 
signalling mediators including tumour necrosis factor (TNF)-receptor associated 
factor 3 (TRAF3) leading to the activation of downstream effector molecules such as 
the transcription factors IFN regulatory factor-3 (IRF-3) and nuclear factor-κB (NF-κB) 
and ultimately the expression of IFN-β, IFN-λ and a small subset of IFN-stimulated 
genes (ISGs) (Arnaud et al., 2011; Loo and Gale, 2011; Takeuchi and Akira, 2009).  
Secretion of IFN-β induces an antiviral state that also extends to surrounding 
uninfected cells by binding to the type I IFN receptor (IFNAR) and thereby activating 
the Janus kinase (JAK)/ signal transducer and activator of transcription (STAT) 
signalling pathway, which results in the induction of more than 300 ISGs with 
antiviral, antiproliferative and immunomodulatory functions. A few examples include 
2’–5’ oligoadenylate synthetase 1 (OAS1)/RNAse L, which degrades viral and cellular 
RNA (Guo et al., 2004), and dsRNA-specific adenosine deaminase 1 (ADAR1), 
which converts adenosine to inosine in dsRNA leading to the accumulation of 
mutations during viral replication (Taylor et al., 2005). 
Three subtypes of IFN-λ exist: IFN-λ1 (IL-29), IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B) 
(Sheppard et al., 2003). All subtypes bind to the same heterodimeric receptor 
consisting of the IL-28 receptor α-chain and the IL-10 receptor β-chain. Although they 
bind to a different receptor, type III interferons also activate the JAK-STAT signalling 
pathway. Furthermore, the pattern of ISGs induced by IFN-λ in liver cells is very 
similar to the one induced by IFN-α, even though the kinetics of ISG expression are 
different (Marcello et al., 2006).    
Interestingly, several single nucleotide polymorphisms (SNPs) upstream of the IFNL3 
gene have been associated with spontaneous clearance of HCV infection (Thomas et 
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al., 2009) as well as improved response to IFN-α therapy (Ge et al., 2009; Suppiah et 
al., 2009; Tanaka et al., 2009), but the mechanism behind this association is still 
unknown.  
HCV has evolved several ways to evade the innate immune responses. The NS3/4A 
protein can cleave TRIF (Li et al., 2005a) and MAVS (Foy et al., 2005; Li et al., 
2005b; Meylan et al., 2005), thereby blocking TLR3, RIG-I and PKR signalling. In 
addition, HCV core can interfere with JAK/STAT signalling and therefore ISG 
expression in several ways: It can inhibit STAT1 activation (Lin et al., 2006), induce 
suppressor of cytokine signalling 3 (SOCS3) (Bode et al., 2003), which is an inhibitor 
of the JAK/STAT pathway, and inhibit ISG factor 3 binding to IFN-stimulated 
response elements. 
Another cell type that is involved in the innate immune response against HCV are 
natural killer (NK) cells (reviewed in (Cheent and Khakoo, 2011)), which are more 
frequently found in the liver than in the blood (Corado et al., 1997). NK cell were 
originally associated with HCV infection outcome in an immunogenetic study of the 
killer cell immunoglobulin-like receptor (KIR) genes and their human leukocyte 
antigen (HLA)-C ligands (Khakoo et al., 2004). In this study KIR2DL3 and its group 1 
HLA-C ligand was associated with protection from chronic HCV infection in PWID. 
The protective effect has been attributed to the lower avidity binding of KIR2DL3 to 
HLA-C than other inhibitory KIRs and NK cells expressing this inhibitory receptor 
would therefore have a lower activation threshold allowing for stronger and more 
rapid antiviral effector functions (Fadda et al., 2010; Moesta et al., 2008). Another 
possible explanation might be found in a recent study by Thöns et al., who found a 
negative correlation between the strong inhibitory NK cell receptor NKG2A and 
KIR2DL3 and the protective effect might thus be mediated by the absence of NKG2A 
(Thoens et al., 2014). 
In addition to genetic studies, NK cells have also been found to be activated in 
acutely infected patients as indicated by an increased expression of the activating 
receptor NKG2D compared to healthy subjects (Amadei et al., 2010). This was 
accompanied by increased production of IFN-γ and cytotoxicity. Even though the 
cytotoxicity of NK cells was not altered in chronically infected patients, conflicting 
data exists with regard to cytokine production and in particular IFN-γ production 
(Ahlenstiel et al., 2010; Amadei et al., 2010; Golden-Mason et al., 2008; Oliviero et 
al., 2009). 
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Only limited data exists on the evasion of NK cell responses during HCV infection. It 
has been suggested that NS5A-containing apoptotic bodies can trigger the 
production of IL-10 and decrease the IL-12 production by monocytes, which would 
lead to a downregulation of NKG2D on NK cells (Sène et al., 2010). Crosslinking of 
CD81 by soluble glycoprotein E2 and subsequent interaction with NK cells also leads 
to inhibitory signalling in NK cells resulting in reduced cytotoxicity and IFN-γ 
production in vitro (Crotta et al., 2002; Tseng and Klimpel, 2002), but the 
physiological role of this phenomenon is debatable, as direct exposure to infectious 
HCV particles did not have the same effect (Crotta et al., 2010; Farag et al., 2011). 
 
1.8.2 Adaptive immune response 
1.8.2.1 Humoral immune response 
In most acutely infected patients, HCV-specific antibodies (Abs) against epitopes 
within the structural and non-structural proteins become detectable approximately 7-8 
weeks after infection (Pawlotsky, 1999), but most of these have no antiviral activity, 
as only a small fraction is made up of neutralizing antibodies (nAbs) that can inhibit 
virus binding, entry or uncoating. Multiple linear, conformational and discontinuous 
epitopes that are targeted by nAbs have been identified in the HCV envelope 
glycoproteins E1 and E2 including a “hot-spot” in and adjacent to HVR-1 (Sabo et al., 
2011). It has been shown that nAbs target entry at a step after initial binding of HCV, 
most likely by interrupting HCV E2-CD81 or HCV E2-SR-BI interactions or by 
inhibiting membrane fusion (Haberstroh et al., 2008). Nevertheless, the role of nAbs 
during acute HCV infection and particularly viral clearance is incompletely 
understood.  
On the one hand, spontaneous viral clearance without seroconversion has been 
observed in chimpanzees (Cooper et al., 1999) as well as humans (Post et al., 2004), 
including immunocompromised patients with primary antibody deficiencies (e.g. 
hypogammaglobulinaemic patients) (Christie et al., 1997). Taken together these 
findings seem to indicate that antibody responses against HCV are not necessarily 
required for viral clearance. Furthermore, numerous studies have suggested that 
patients with acute-resolving infection lack nAbs, while patients with chronic infection 
develop these after establishment of persistence (Bartosch et al., 2003; Kaplan et al., 
2007; Logvinoff et al., 2004; Netski et al., 2005; Zeisel et al., 2008). 
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On the other hand, the induction of nAbs during early infection has been associated 
with spontaneous viral clearance in a study of a single-source genotype 1b outbreak 
in East Germany caused by a contaminated anti-D immunoglobulin preparation 
(Pestka et al., 2007). In the same cohort, a delayed development of nAbs was 
observed in patients with chronic HCV infection. A study by Osburn et al., who found 
that HCV reinfection and subsequent viral clearance in PWID was associated with 
the induction of cross-reactive humoral responses, provides further evidence for a 
beneficial role of nAbs (Osburn et al., 2010). It has also been shown that nAbs drive 
sequence evolution in vivo during acute infection and resolution of infection has been 
linked to an antibody response that effectively neutralized autologous time-matched 
viruses (Dowd et al., 2009). 
Several mechanisms for the evasion of humoral immune responses have been 
suggested. Viral escape in epitopes targeted by nAbs might play a role (Farci et al., 
1996). In addition, HVR-1 might function as a decoy for nAbs, as it stimulates strong 
immune responses responsible for viral variant selection that are nevertheless 
unable to clear the infection (von Hahn et al., 2007). Interaction of the HCV 
glycoproteins with SR-B1 and high-density lipoprotein (HDL) may protect from nAbs 
(Logvinoff et al., 2004) and some gylcoproteins on E2 also modulate cell entry and 
protect from nAbs (Falkowska et al., 2007; Helle et al., 2007). Furthermore, binding 
of non-neutralizing Abs may prevent the binding of nAbs (Zhang et al., 2007). Recent 
studies also suggest that HCV can also spread by direct cell-to-cell transfer, thereby 
circumventing neutralisation (Brimacombe et al., 2011; Timpe et al., 2008; Witteveldt 
et al., 2009). 
 
1.8.2.2 Cellular immune response 
Both CD4+ and CD8+ T cell responses play a critical role during HCV infection. T cell 
responses against HCV become detectable after a delay of approximately 6-12 
weeks.  
One indicator of the importance of HCV-specific CD4+ T cells for HCV clearance is 
the association of certain HLA class II alleles with HCV infection outcome in genetic 
studies. As CD4+ T cells recognize antigen in the context of major histocompatibility 
complex (MHC) class II presentation, these cells and their targeting of specific 
epitopes has been linked to differential infection outcome. The HLA class II alleles 
most reproducibly correlated with favourable infection outcome in heterogeneous 
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study cohorts are DRB1*1101 and DQB1*0301, which are in linkage disequilibrium 
(Hong et al., 2005). However, in a single-source outbreak in Ireland, DRB1*0101, 
DRB1*0401 and DRB1*15 were associated with viral clearance (McKiernan et al., 
2004). Interestingly, most CD4+ T cell epitopes discovered so far are restricted by 
“protective” HLA alleles, even though these epitopes are in general highly 
promiscuous and often restricted by multiple HLA class II alleles (reviewed in 
(Walker, 2010)). 
The role of CD4+ T cells on HCV infection outcome can at least partly be attributed to 
the fact that they provide support for CD8+ T cells during the acute phase of infection. 
Loss of helper activity has been linked to poor CD8+ T cell function in humans 
(Francavilla et al., 2004; Kaplan et al., 2008; Urbani et al., 2006). In vivo experiments 
in chimpanzees corroborate these findings, as antibody-mediated depletion of CD4+ 
T cells in previously protected animals led to loss of viral control and emergence of 
escape variants in MHC class I epitopes (Grakoui et al., 2003). 
In addition, studies in patients with acute HCV infection found strong, multi-specific 
and sustained HCV-specific CD4+ T cell responses in patients that subsequently 
resolved infection (Day et al., 2002; Diepolder et al., 1995, 1997; Gerlach et al., 
1999; Missale et al., 1996; Schulze zur Wiesch et al., 2005). These CD4+ T cells 
show better proliferation and IL-2, IFN-γ and TNF-α production. Recently, one 
particular CD4+ T cell subset has been associated with viral clearance, namely 
CD161highCCR6+CD26+CD4+ T cells that express IL-17A as well as IL-21 and Th17-
lineage-specific transcription factors (Kared et al., 2013) (figure 1.4). 
When broad CD4+ T cell responses can be detected during the acute phase in 
patients who go on to develop chronic infection, these cells later undergo rapid 
exhaustion with sequential loss of IL-2 production, proliferation and IFN-γ secretion 
(Gerlach et al., 1999; Semmo et al., 2005) as well as elevated expression of 
inhibitory receptors such as T cell immunoglobulin domain and mucindomain 3 (TIM-
3), programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) 
(Raziorrouh et al., 2011). 
CD8+ T cells are critical for viral clearance. Similar to MHC class II alleles, several 
MHC class I alleles have also been linked to HCV infection outcome. In particular, 
HLA-A*03, HLA-B*27, HLA-B*57 and HLA-C*01 have been associated with viral 
clearance of genotype 1 infection (Kim et al., 2011; Kuniholm et al., 2010; McKiernan 
et al., 2004), while HLA-B*08, HLA-B*18 and HLA-C*04 have been linked to viral 
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persistence (Kim et al., 2011; McKiernan et al., 2004; Thio et al., 2002). The 
protective effects of HLA-A*03, HLA-B*27 and HLA-B*57 have been linked to 
immunodominant CD8+ T cell epitopes (Fitzmaurice et al., 2011; Neumann-Haefelin 
et al., 2010; Oniangue-Ndza et al., 2011). 
The appearance of vigorous HCV-specific CD8+ T cell responses in the liver and the 
peripheral blood targeting multiple epitopes has been temporally linked with initial 
control of acute phase viremia and a peak in serum transaminases (Cooper et al., 
1999; Cox et al., 2005a; Grüner et al., 2000; Lechner et al., 2000; Thimme et al., 
2001, 2002). Importantly, CD8+ T cells have also been shown to play a critical role in 
viral control in vivo. In an HCV-infected chimpanzee antibody-mediated depletion of 
CD8+ T cells led to loss of viral control, until the HCV-specific CD8+ T cell responses 
recovered (Shoukry et al., 2003). 
In general, CD8+ T cells can eliminate virus-infected hepatocytes in two different 
ways: non-cytolytic, cytokine-mediated inhibition of replication, which does not 
require the destruction of the infected cell, and perforin/granzyme-mediated or 
surface death receptor-mediated cytolytic destruction of infected cells. In in vitro 
experiments virus-specific CD8+ T cells have been shown to exert strong antiviral 
effector functions primarily via IFN-γ production and only to a lesser degree via direct 
cytolytic effector functions (Jo et al., 2009). This finding has also been confirmed in 
chimpanzees, where viral clearance in the acute phase can occur without elevated 
transaminase levels and only minimal histological evidence for liver cell injury, but 
with detectable IFN-γ messenger RNA (mRNA) levels (Su et al., 2002). 
During the acute phase of HCV infection HCV-specific CD8+ T cells exhibit a stunned 
phenotype that is characterised by impaired proliferation, cytotoxicity and IFN-γ 
production irrespective of eventual infection outcome (Lechner et al., 2000; Thimme 
et al., 2001; Urbani et al., 2006). In addition, these CD8+ T cells also exhibit elevated 
surface expression of PD-1 (Kasprowicz et al., 2008). However, this increased PD-1 
expression can be transient in acute HCV infection and shows a similar pattern as 
the activation marker CD38 (Kasprowicz et al., 2008; Shin et al., 2013). PD-1 can 
therefore probably be considered as a marker of activation rather than exhaustion on 
HCV-specific CD8+ T cells during acute infection. In patients who later resolve HCV 
infection PD-1 is eventually downregulated and the antiapoptotic marker B cell 
lymphoma-2 (Bcl-2) and the IL-7 receptor α-chain CD127, which also serves as a 
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memory marker, get upregulated instead (figure 1.4) (Shin et al., 2013; Thimme et 
al., 2001; Urbani et al., 2006). 
 
 
Figure 1.4: Phenotype of CD4+ and CD8+ T cells during acute, chronic and resolved 
HCV infection 
A strong and maintained CD4+ T cell response appears to be a critical factor for the outcome of acute 
HCV infection. In its presence, HCV-specific CD8+ T cell populations with an initially ‘‘stunned’’ 
phenotype acquire multiple effector functions (top). In the absence or loss of a strong CD4+ T cell 
response, CD8+ T cells develop exhausted phenotypes, which are attributed to chronic antigen-
specific stimulation. Those CD8+ T cells that target HCV escape variants remain functional with a 
memory phenotype in the chronic phase of infection. Treg: regulatory T cell. Modified from (Park and 
Rehermann, 2014). 
 
In most patients with chronic infection, HCV-specific CD8+ T cells are also present, 
but are unable to control the infection. Several factors play a role in the failure of the 
CD8+ T cell response. One of these factors is the dysfunction of a large fraction of 
HCV-specific CD8+ T cells during chronic infection, which is characterised by their 
inability to secrete antiviral cytokines such as IFN-γ and their inability to proliferate in 
response to antigen stimulation (Nakamoto et al., 2009; Radziewicz et al., 2007, 
2008; Spangenberg et al., 2005; Wedemeyer et al., 2002). These cells also express 
increased levels of the inhibitory receptor PD-1 (Golden-Mason et al., 2007; 
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Nakamoto et al., 2008; Penna et al., 2007; Radziewicz et al., 2007, 2008) and low 
levels of CD127 (Bengsch et al., 2007; Golden-Mason et al., 2007; Radziewicz et al., 
2007). Very high levels of PD-1 expression have also been associated with caspase-
9 dependent apoptosis of CD8+ T cells in patients that develop chronic infection, 
thereby resulting in the depletion of HCV-specific CD8+ T cells (Radziewicz et al., 
2008). In addition, other inhibitory receptors like Tim-3, CD160, 2B4 (CD244) and 
CTLA-4 as well as the T cell senescence marker killer-cell-lectin-like receptor G1 
(KLRG1) are also upregulated (Bengsch et al., 2010; Golden-Mason et al., 2009; 
Nakamoto et al., 2009). The function of HCV-specific CD8+ T cells co-expressing 
multiple inhibitory receptors could only partially be restored in vitro by blockade of 
PD-1 (Bengsch et al., 2010) and full restoration of function necessitated the blockade 
of more than one receptor (Nakamoto et al., 2009). The mechanisms causing this 
exhaustion of HCV-specific CD8+ T cells are incompletely understood, but 
contributing factors probably include the lack of CD4+ T cell help mentioned above as 
well as the action of regulatory T cells or cytokines. 
Increased numbers of CD4+CD25+ T cells have been found in chronically HCV-
infected patients compared to patients with resolved infection and healthy controls 
(Boettler et al., 2005; Cabrera et al., 2004; Sugimoto et al., 2003). These regulatory T 
cells can suppress both the IFN-γ production and the proliferation of virus-specific 
CD8+ T cells in vitro in a cell-cell contact dependent manner (Sugimoto et al., 2003). 
Virus-specific regulatory CD8+ T cells also exist. These cells have been found in the 
liver of HCV infected patients and express high levels of the inhibitory cytokine IL-10 
(Abel et al., 2006). 
The liver microenvironment probably also contributes to the dysfunction of HCV-
specific CD8+ T cells. Several mechanisms that bias immune responses in the liver 
towards tolerance have been proposed. These include antigen-presenting cells, such 
as liver dendritic cell subsets as well as liver sinusoidal dendritic cells and hepatic 
stellate cells, that might induce immune suppression via different mechanisms 
including the secretion of inhibitory cytokines like IL-10 and transforming growth 
factor (TGF)-β, the expression of inhibitory molecules like programmed death-ligand 
1 (PD-L1) on Kupffer cells, pDCs, liver sinusoidal endothelial cells (LSECs), stellate 
cells and hepatocytes or the failure to provide sufficient co-stimulation (reviewed in 
(Crispe, 2011; Protzer et al., 2012; Thomson and Knolle, 2010)). Hepatocytes have 
also been shown to function as antigen-presenting cells leading to the activation of 
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dysfunctional CD8+ T cells (Bowen et al., 2004) and CD8+ T cells that are prone to 
apoptosis in a Bcl-2-interacting mediator of death (Bim)-dependent manner in murine 
models (Holz et al., 2008). The individual contributions of these factors to HCV-
specific CD8+ T cell dysfunction still need to be clarified. 
Not all HCV-specific CD8+ T cells in chronically infected patients have an exhausted 
phenotype, but functional CD8+ T cells usually target epitopes that harbour escape 
mutations (Bengsch et al., 2010), thereby implicating viral escape as another major 
factor responsible for the failure of the HCV-specific CD8+ T cell response. 
As mentioned above, HCV exists as a viral quasispecies within one patient due to 
both the high replication rate of HCV and its error-prone RdRp, which facilitates the 
selection of escape mutations. Evidence for viral escape has been found both in 
infected chimpanzees (Erickson et al., 2001; Weiner et al., 1995) and patients 
(Chang et al., 1997) and the emergence of escape mutations has been observed 
during acute infection. These escape mutations during acute infection were mainly 
observed in patients who went on to develop chronic infection, but not in patients 
who resolved infection spontaneously (Cox et al., 2005a, 2005b; Tester et al., 2005; 
Timm et al., 2004).  
Many escape mutations are also associated with varying degrees of fitness costs, i.e. 
the replicative capacity of the virus is impaired to some extent (Neumann-Haefelin et 
al., 2008a; Ruhl et al., 2012; Salloum et al., 2008; Uebelhoer et al., 2008). As a 
result, reversions back to the prototype sequence are often observed in the absence 
of immune pressure either due to transmission of the virus to a patients with a 
different HLA allele background (Ray et al., 2005; Timm et al., 2004) or due to 
pregnancy-induced immune tolerance (Honegger et al., 2013).  
Different molecular mechanisms of viral escape have been proposed. Mutations in 
the MHC binding anchors of the epitope, usually position 2 and the terminal amino 
acid, abrogate binding to the MHC molecule, while mutation in the centre of the 
epitope tend to interfere with the recognition by the T cell receptor (TCR) (Söderholm 
et al., 2006). Mutations in the flanking region may additionally interfere with 
proteasomal processing (Kimura et al., 2005; Seifert et al., 2004; Timm et al., 2004). 
In addition, the lack of CD4+ T cell help has been implicated in viral escape in CD8+ T 
cell epitopes (Grakoui et al., 2003). Another study in chimpanzees has associated 
limited TCR diversity with the emergence of viral escape mutations, while a broader 
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TCR repertoire may possibly prevent escape mutations due to cross-reactivity with 
more sequence variants of the same epitope (Meyer-Olson et al., 2004). 
 
1.9 Aim of the study 
CD8+ T cells are an integral part of the immune against HCV. A multitude of factors 
can influence whether the HCV-specific CD8+ T cell response is able to 
spontaneously clear the infection. The viral genotype also plays an important role in 
determining infection outcome. The sequence diversity between different genotypes 
can lead to the presentation of different epitopes to CD8+ T cells. This has already 
been shown to be important, as HLA-B*27 is only associated with viral clearance in 
genotype 1, but not genotype 3, which has been linked to an immunodominant CD8+ 
T cell epitope that is not conserved between the two genotypes. Other known 
differences between genotype 1 and 3 include their different responses to IFN-α 
therapy, with genotype 3 being associated with a more favourable outcome, and the 
association of the IFNL3 genotype with infection outcome and response to therapy. 
Even though these differences are known, only limited data exists about CD8+ T cells 
during genotype 3 infection in general and the factors influencing their ability to clear 
HCV infection. 
Consequently, we wanted to compare what influence different host factors like the 
HLA background and the IFNL3 genotype have on the outcome of HCV infection with 
either genotype 1 or 3 in particular with regard to the HCV-specific CD8+ T cell 
response. Furthermore, we wanted to test, whether both genotype-specific variants 
of an epitope can be recognised in one patient. As a last step, we also wanted to see 
whether the infecting viral genotype influences the exhaustion and deletion of HCV-
specific CD8+ T cells.  
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2 Materials 
2.1 Chemicals, enzymes and reagents 
BD FACS Clean Solution Becton Dickinson (BD) 
BD FACSFlow Sheath Fluid BD 
BD FACSRinse Solution BD 
BD FACS Shutdown Solution BD 
Biocoll Separating Solution Biochrome 
Dimethylsulfoxid (DMSO) Roth 
Deoxynucleotide Triphosphate (dNTP) Mix myBudget 
Dulbecco's Phosphate-Buffered Saline, 1X (PBS) Gibco 
Ethanol Sigma-Aldrich 
GoTaq Flexi Deoxyribonucleic acid (DNA) Polymerase Promega 
IC Fixation Buffer  eBioscience 
Isopropanol Sigma-Aldrich 
Permeabilization Buffer (10X) eBioscience 
 
2.2 Cell culture media and additives 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 1M 
PAA 
Brefeldin A (BFA) Sigma Aldrich 
Fetal bovine serum (FBS) Biochrome  
Penicillin/Streptomycin (100X) PAA 
Roswell Park Memorial Institute (RPMI) 1640 + L-Glutamin  PAA 
IL-2 Roche 
CD28/CD49d Costimulatory Reagent BD 
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2.3 Composition of cell culture media 
R10         RPMI 1640 
10% FBS 
10 mM HEPES 
         100 U/ml penicillin  
100 µg/ml streptomycin 
Freezing medium       FBS 
         10% DMSO 
 
2.4 Commercial kits 
LightCycler FastStart DNA MasterPLUS HybProbe 
polymearse chain reaction (PCR) Kit  
Roche 
LightSNiP Typing Assay rs12979860 Homo sapiens   TIB MOLBIOL 
QIAamp Viral RNA Mini Kit  Qiagen 
QIAamp DNA Blood Mini Kit Qiagen 
Qiagen OneStep reverse transciptase (RT)-PCR Kit Qiagen 
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2.5 Antibodies and other staining reagents for flow cytometry 
All conjugated antibodies were stored at 4 °C and all unconjugated antibodies were 
stored at -20 °C. Fixable Viability Dyes were aliquoted and stored at -80 °C to void 
multiple freeze/thaw cycles. If not otherwise indicated, all antibodies were mouse 
anti-human. 
 
Table 2.1: Antibodies and other staining reagents 
specificity fluorochrome clone dilution concentration company 
BimS/EL/L  
(rat anti-human) 
unconjugated 3C5 1:10   Enzo Life 
Sciences 
CD3 Peridinin 
chlorophyll 
protein (PerCP)- 
Cyanine (Cy)5.5 
OKT3 
 
1:1000 0.05mg/ml 
 
 
CD4 Phycoerythrin 
(PE) 
 
RPA-T4 1:1000 0.2 mg/ml eBioscience 
CD4 Allophycocyanin 
(APC)-eFluor780 
RPA-T4 1:500 0.1 mg/ml eBioscience 
CD8 eFluor450 RPA-T8 1:500  eBioscience 
CD8 PerCP-Cy5.5 RPA-T8 1:400 0.05 mg/ml eBioscience 
CD8 APC  RPA-T8 1:400 0.012 mg/ml eBioscience 
CD38 APC HIT2 1:50  BD 
CD127 PE-Cy7 HIL-7R-M21 1:20  BD 
Fixable 
Viability Dye 
eFluor780 n.a. 1:5000  eBioscience 
Fixable 
Viability Dye 
eFluor506 n.a. 1:1000  eBioscience 
IgG2a  
(goat anti-rat) 
Fluorescein 
isothiocyanate 
(FITC) 
polyclonal 1:200  1 mg/ml Bethyl 
Laboratories 
IFN-γ FITC 4S.B3 1:1000 0.5 mg/ml eBioscience 
IFN-γ PE-Cy7 4S.B3 1:1500 0.2 mg/ml eBioscience 
Vβ 1 PE BL37.2 1:200  Beckman 
Coulter  
Vβ 2 FITC MPB2D5 1:100  Beckman 
Coulter  
Vβ 3 FITC CH92 1:20  Beckman 
Coulter 
Vβ 4 FITC WJF24 1:20  Beckman 
Coulter 
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specificity fluorochrome clone dilution concentration company 
Vβ 5.1 APC LC4 1:100 0.1 mg/ml eBioscience 
Vβ 5.2 PE 36213 1:10  Beckman 
Coulter 
Vβ 5.3 APC 3D11 1:100 0.1 mg/ml eBioscience 
Vβ 7.1 PE ZOE 1:20  Beckman 
Coulter 
Vβ 7.2 PE ZIZOU4 1:100  Beckman 
Coulter 
Vβ 8 eFluor450 JR-2 1:500 0.05 mg/ml eBioscience 
Vβ 9 APC AMKB1-2 1:100 0.05 mg/ml eBioscience 
Vβ 11 APC C21 1:20  Beckman 
Coulter 
Vβ 12 FITC VER2.32.1 1:20  Beckman 
Coulter 
Vβ 13.1 FITC H131 1:100 0.2 mg/ml eBioscience 
Vβ 13.2 PE H132 1:100 0.0025 mg/ml eBioscience 
Vβ 13.6 PE JU74.3 1:20  Beckman 
Coulter 
Vβ 14 PE CAS1.1.3 1:20  Beckman 
Coulter 
Vβ 16 FITC TAMAYA1.2 1:100  Beckman 
Coulter 
Vβ 17 PE E17.5F3.15.13 1:20  Beckman 
Coulter 
Vβ 18 PE BA62.6 1:20  Beckman 
Coulter 
Vβ 20 FITC ELL1.4 1:10  Beckman 
Coulter 
Vβ 21.3 FITC IG125 1:10  Beckman 
Coulter 
Vβ 22 FITC IMMU 546 1:50  Beckman 
Coulter 
Vβ 23 PerCP-eFluor710 AF23 1:50 0.1 mg/ml eBioscience 
n.a.: not applicable 
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TCR Vβ antibodies were grouped into 9 pools for flow cytometric analysis of the Vβ 
repertoire. Vβ segments and corresponding antibodies used in these pools, which 
cover about 70% of the normal human TCR Vβ repertoire of CD3+ lymphocytes, are 
shown in table 2.2. 
 
Table 2.2: TCR Vβ pools  
pool ID Vβ* (#) fluorochrome 
pool 1 Vβ 3 (TRBV28) FITC 
 Vβ 7.1 (TRBV4-1, TRBV4-2, TRBV4-3) PE 
 Vβ 5.3 (TRBV5-5) APC 
pool 2 Vβ 16 (TRBV14) FITC 
 Vβ 17 (TRBV19) PE 
 Vβ 9 (TRBV3-1) APC 
pool 3 Vβ 20 (TRBV30) FITC 
 Vβ 18 (TRBV18) PE 
 Vβ 5.1 (TRBV5-1) APC 
pool 4 Vβ 13.1 (TRBV6-5, TRBV6-6, TRBV6-9) FITC 
 Vβ 13.6 (TRBV6-6) PE 
 Vβ 8 (TRBV12-3, TRBV12-4) eFluor450 
pool 5 Vβ 2 (TRBV20-1) FITC 
 Vβ 5.2 (TRBV5-6) PE 
pool 6 Vβ 21.3 (TRBV11-2) FITC 
 Vβ 1 (TRBV9) PE 
 Vβ 23 (TRBV13) PerCP-eFluor710 
pool 7 Vβ 22 (TRBV2) FITC 
 Vβ 14 (TRBV27) PE 
 Vβ 11 (TRBV25-1) APC 
pool 8 Vβ 4 (TRBV29-1) FITC 
 Vβ 13.2 (TRBV6-2) PE 
pool 9 Vβ 12 (TRBV10-3) FITC 
 Vβ 7.2 (TRBV4-3) PE 
* nomenclature according to Wei et al. (Wei et al., 1994) 
# IMGT nomecalture (Lefranc, 2003; Lefranc et al., 1999) 
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2.6 MHC class I dextramers 
MHC class I dextramer consist of a dextran polymer backbone carrying an optimized 
number of MHC class I molecules as well as fluorochrome molecules. All MHC class 
I dextramers were ordered from Immundex and were stored at 4 °C in the dark. 
 
Table 2.3: MHC class I dextramers 
ID position protein genotype (GT) 
HLA-
restriction sequence fluorochrome 
p1 1436 NS3 1a/1b/3a HLA-A*01 ATDALMTGY PE 
p11 1406 NS3 1a HLA-A*02 KLVALGINAV PE 
p20 2841 NS5B 1a/1b HLA-B*27 ARMILMTHF FITC and PE 
p24 1073 NS3 1a/1b HLA-A*02 CINGVCWTV PE 
p47 2594 NS5B 1a HLA-A*02 ALYDVVTKL PE 
p67 1273 NS3 1a/1b HLA-A*02 GVDPNIRTGV PE 
p99 1373 NS3 1a/1b/3a HLA-B*51 IPFYGKAI PE 
p384 840 NS2 3a HLA-B*27 GRLIWWNQY PE 
p387 942 NS2 3a HLA-B*27 GRWFNTYLY APC 
CMV 495 pp65 n.a. HLA-A*02 NLVPMVATV PE 
Flu 58 matrix n.a. HLA-A*02 GILGFVFTL PE 
 
2.7 Oligonucleotides 
All primers were ordered from biomers.net. Lyophilised primers were reconstituted in 
RNAse free water at a concentration of 10 pmol/µl and stored at -20 °C. 
 
Table 2.4: Oligonucleotides used for PCR 
ID GT position sequence amplified fragment  (PCR round) 
HCV1a-2e-F 1a 2531 CGTCTGCTCCTGCTTGTGG NS2 (1) 
HCV1a-3a-F 1a 2718 ATGTGGCCTCTCCTCCTGC NS2 (2) 
HCV1a-3b-R 1a 3390 ACCCCTTGGAGACCATTCC NS2 (2) 
HCV1a-3c-R 1a 3746 TCCRAATGGAGACCAAGC NS2 (1) 
HCV1a-3b-F 1a 2919 TGGRTTCCCCCCCTCAACG NS3 (1) 
HCV1a-3c-F 1a 3271 TCCRAATGGAGACCAAGC NS3 (2) 
HCV1a-4d-R 1a 5306 ACCCAGGTGCTCGTGACG NS3 (2) 
HCV1a-4e-R 1a 5519 GGGCCCTTCTGCTTGAACTGC NS3 (1) 
HCV1a-7b-F 1a 7952 CCACATCAACTCCGTGTGG NS5B (1) 
HCV1a-7d-F 1a 8625 GCTATGACCAGGTACTCCG NS5B (2) 
HCV1a-7e-R-int 1a 9325 CCTGCAGCAAGCAGGAGTAGGC NS5B (2) 
HCV1a-3’prime end 1a 9384 TAAGAGGCCGGAGTGTTTAYCC NS5B (1) 
HCV1b-2d-F 1b 2415 CTCCAYCAGAACATCGTGG NS2 (1) 
HCV1b-2e-F 1b 2650 TGTTCTTCTGTGCYGCCTGG NS2 (2) 
HCV1b-3b-R 1b 3400 ATGGGCGCRAGGAGTCGC NS2 (2) 
HCV1b-3c-R 1b 3717 CCAARTAAAGGTCCGAGCTGCC NS2 (1) 
HCV1b-3274-F 1b 3274 GACATGGAGACCAARRTCATCA NS3 (1) 
HCV1b-3353-F 1b 3353 CCGAAGGGGRARGGAGAT NS3 (2) 
HCV1b-5502-R 1b 5502 TGYTCGGCGAGCTGCATYCC NS3 (2) 
HCV1b-5638-R 1b 5638 TCCCGCTGATGAARTTCC NS3 (1) 
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ID GT position sequence amplified fragment  (PCR round) 
HCV1b-sv365s 1b 7254 GACTACGTCCCTCCMGTGGTAC NS5B (1) 
HCV1b-sv394s 1b 7412 GTCGGCCGTCGACAGCGGCACRGCRAC NS5B (2) 
HCV1b-sv347as 1b 8960 AGGTAGGTCAAGTGGYTCAATG NS5B (2) 
HCV1b-sv350as 1b 9006 GTGGAGTGTAAATGCGCTAAG NS5B (1) 
HCV3a-2367-F 3a 2367 CCTTGCTCYTTCACGCCCATG NS2 (1) 
HCV3a-2756-F 3a 2756 CAACGGGCGTAYGCTTGG NS2 (2) 
HCV3a-3974-R 3a 3974 TCAGARAARGATGGRGACC NS2 (2) 
HCV3a-4055-R 3a 4055 CYTTYGTGCTCTTACCRCTGC NS2 (1) 
HCV3a-3256-F 3a 3256 CTAGCAGTGGCCACTGAACC NS3 (1) 
HCV3a-3341-F 3a 3341 ATATTCTTTGCGGGCTGC NS3 (2) 
HCV3a-5439-R 3a 5439 CACCTCYTTRTCTGGAACG NS3 (2) 
HCV3a-5452-R 3a 5452 TATTGTTGRTACARCACCTC NS3 (1) 
 
2.8 Peptides 
All HCV-specific peptides were ordered from peptides&elephants or EMC at 70% 
purity. The lyophilised peptides were reconstituted with DMSO at a concentration of 
20 mg/ml and stored at -80 °C. Working solutions were prepared at a concentration 
of 1 mg/ml by dilution of the stock solutions with RPMI medium without any additives. 
Working solutions were stored at -20 °C.  
 
Table 2.5: HCV-specific peptides contained in HLA-matched peptide pools 
HLA-type ID aa position protein genotype sequence 
A*01 p1 1436 NS3 1a, 1b, 3a ATDALMTGY 
A*02 p11 1406 NS3 1a KLVALGINAV 
 p14 1131 NS3 1a, 1b YLVTRHADV 
 p24 1073 NS3 1a, 1b CINGVCWTV 
 p42 1406 NS3 1b KLSGLGLNAV 
 p47 2594 NS5B 1a ALYDVVTKL 
 p67 1273 NS3 1a, 1b GVDPNIRTGV 
 p96 1987 NS5A 1a VLSDFTTWL 
 p119 2479 NS5B 1b VLDDHYWDV 
A*03 p126 2510 NS5B 1b KLTPPHSAK 
 p193 1858 NS4B 1a, 1b GVAGALVAFK 
 p211 43 Core 1a, 1b, 3a RLGVRATRK  
 p212 51 Core 1a, 1b, 3a KTSERSQPR  
 p229 2587 NS5B 1a, 1b RVCEKMALY 
A*03/A*11 p16 1261 NS3 1a, 1b TLGFGAYMSK 
 p34 1635 NS3 1a, 1b VTLTHPITK 
 p38 1227 NS3 1a, 1b HLHAPTGSGK 
 p59 1227 NS3 3a YLHAPTGSGK 
A*11 p17 1265 NS3 1a, 1b GAYMSKAHGV 
 p154 2 Core 1a, 1b STNPKPQKK 
 p210 1 Core 1a, 1b MSTNPKPQK  
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HLA-type ID aa position protein genotype sequence 
A*11 p220 621 E2 1a TINYTIFK  
A*23/A*24 p156 838 NS2 1a YISWCLWWL 
A*24 p12 1031 NS3 1b AYSQQTRGL 
 p13 1100 NS3 1a, 1b, 3a MYTNVDQDL 
A*24 p65 1292 NS3 1a, 1b, 3a TYSTYGKFL 
 p155 674 E2 1a, 1b ILPCSFTTL 
A*25 p142 1758 NS4B 1a, 1b EAFWAKHMW 
 p143 1758 NS4B 1a, 1b variant ETFWAKHMW 
 p189 1744 NS4B 1a EVITPAVQTNW 
 p223 831 NS2 1a LSPYYKRYIS  
 p231 2818 NS5B 1a, 1b, 3a TARHTPVNSW 
A*26 p30 1534 NS3 1a, 1b, 3a ETTVRLRAY 
 p187 2416 NS5A/B 1a, 1b DVVCCSMSY 
A*26/B*18 p144 1582 NS3 1b DNFPYLVAY 
A*29 p221 790 p7 1a FYGMWPLLL  
 p222 827 NS2 1a MALTLSPY  
A*68 p50 1175 NS3 1a, 1b HAVGIFRAAV 
B*07 p114 1111 NS3 1b WPAPSGARSL 
 p148 2836 NS5B 1b APTLWARMVL 
 p149 2000 NS5A 1b LPRLPGVPF 
 p184 41 Core 1a, 1b, 3a GPRLGVRAT 
 p214 111 Core 1a, 1b, 3a DPRRRSRNL  
B*08 p3 1395 NS3 1a, 1b, 3a HSKKKCDEL 
 p61 1611 NS3 1a, 1b, 3a LIRLKPTL 
B*13 p32 1627 NS3 1a, 1b RLGAVQNEV 
 p33 1627 NS3 3a RLGPVQNEI 
B*15 p39 1265 NS3 3a GSFMSRAYGI 
 p117 2450 NS5B 1b LLRHHNMVY 
 p146 2466 NS5B 1b SQRQKKVTF 
B*27 p20 2841 NS5B 1a, 1b ARMILMTHF 
 p56 1492 NS3 3a GRGRlGTYRY 
 p58 1492 NS3 1a GRGKPGIYRF 
 p185 2820 NS5B 1a, 1b, 3a ARHTPVNSW 
B*35 p22 1359 NS3 1a, 1b, 3a HPNIEEVAL 
 p186 2163 NS5A 1a, 1b EPEPDVAVL 
 p191 2000 NS5A 1b variant LPKLPGVPF 
 p215 169 Core 1a, 1b, 3a LPGCSFSIF  
 p216 234 E1 1a NASRCWVAM  
 p219 589 E2 1a HPEATYSRC 
 p225 1695 NS4A 1a, 1b IPDREVLY 
B*37 p190 1966 NS4B/5A 1a SECCTPCSGSW 
B*38 p192 2218 NS5A 1a NHDSPDAEL 
 p227 1941 NS4B 1a AARVTAIL 
 p230 2793 NS5B 1a HDGAGKRKYYL 
B*40 p73 530 E2 1a GENDTDVFVL 
 p77 2152 NS5A 1a HEYPVGSQL 
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HLA-type ID aa position protein genotype sequence 
B*40 p79 2336 NS5A 1a TESTVSTAL 
 p83 2266 NS5A 1a, 1b REISVPAEIL 
 p87 1871 NS4B 1a, 1b GEVPSTEDL 
 p91 654 E2 1a, 1b LEDRDRSEL 
 p93 453 E2 1a PERLASCRPL 
 p106 2142 NS5A 1a REEVSFRVGL 
 p107 2152 NS5A 1a HEYPVGSQL 
 p109 530 E2 1b GENETDVLLL 
 p110 1871 NS4B 1b GEMPSTEDL 
 p111 2142 NS5A 1b REEVTFQVGL 
B*44 p213 88 Core 1b NEGLGWAGW  
B*51 p99 1373 NS3 1a, 1b, 3a IPFYGKAI 
 p217 489 E2 1a YPPKPCGI  
B*57 p19 2629 NS5B 1a, 1b KSKKTPMGF 
 p21 541 E2 1a NTRPPLGNW 
B*58 p218 521 E2 1a, 1b RSGAPTYSW 
 p224 1596 NS3 1a, 1b, 3a RAQAPPPSW 
 p228 1968 NS4B 1a CTTPCSGSW 
 
Table 2.6: Predicted HLA-B*27 restricted HCV-specific peptides 
HLA-type ID aa position protein genotype sequence 
B*27 p20 2841 NS5B 1a, 1b ARMILMTHF 
 p56 1492 NS3 3a GRGRlGTYRY 
 p57 1492 NS3 1b GRGRRGIYRF 
 p58 1492 NS3 1a GRGKPGIYRF 
 p185 2820 NS5B 1a, 1b, 3a ARHTPVNSW 
 p375 39 Core 1a, 1b, 3a RRGPRLGVR 
 p376 61 Core 1a, 1b, 3a RRQPIPKAR 
 p377 73 Core 1b GRAWAQPGY 
 p378 113 Core 1a, 1b, 3a RRRSRNLGKV 
 p379 316 E1 1a, 1b, 3a HRMAWDMMM 
 p380 547 E2 3a GRWFGCTWM 
 p381 729 E2 3a ARVCVALWL 
 p382 780 p7 1a GRWVPGAAY 
 p383 840 NS2 1b ARLIWWLQY 
 p384 840 NS2 3a GRLIWWNQY 
 p385 869 NS2 1a GRDAVILLM 
 p386 919 NS2 1b IRACMLVRK 
 p387 942 NS2 3a GRWFNTYLY 
 p388 1004 NS2 3a ARLGREVLL 
 p389 1144 NS3 1a, 1b RRGDSRGSL 
 p390 1487 NS3 1a RRGRTGRGK 
 p391 1487 NS3 1b, 3a RRGRTGRGR 
 p392 1492 NS3 3a GRGRLGTYR 
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HLA-type ID aa position protein genotype sequence 
B*27 p393 1494 NS3 3a GRLGTYRYV 
 p394 1499 NS3 1a YRFVAPGER 
 p395 1499 NS3 1b YRFVTPGER 
 p396 1499 NS3 3a YRYVAPGER 
 p397 1958 NS4B 1a RRLHQWISS 
 p398 2094 NS5A 3a RRVGDFHYI 
 p399 2188 NS5A 1a, 1b, 3a RRLARGSPP 
 p400 2279 NS5A 1a RRFAPALPI 
 p401 2328 NS5A 3a RRKRTIQLD 
 p402 2500 NS5B 3a ARMLTIEEA 
 p403 2619 NS5B 3a QRVERLLKM 
 p404 2813 NS5B 1a, 1b, 3a ARAAWETAR 
 p405 2841 NS5B 3a VRMVMMTHF 
 p406 2884 NS5B 1a, 1b QRLHGLSAF 
 p407 2917 NS5B 1a, 3a LRAWRHRAR 
 p408 2920 NS5B 1a WRHRARSVR 
 p409 2920 NS5B 3a WRHRARAVR 
 p410 2922 NS5B 1a HRARSVRAR 
 p411 2922 NS5B 1b HRARSVRAK 
 p412 2922 NS5B 3a HRARAVRAK 
 p413 2924 NS5B 1a ARSVRARLL 
 p414 2924 NS5B 1b ARSVRAKLL 
 p415 2924 NS5B 3a ARAVRAKLI 
 p416 2929 NS5B 1a ARLLSRGGR 
 p417 2936 NS5B 1a GRAAICGKY 
 p418 2936 NS5B 1b GRAATCGKY 
 p419 2985 NS5B 1b SRARPRWFM 
 p420 2985 NS5B 3a SRARTRYLL 
 p421 2989 NS5B 1a PRWFWFCLL 
 p422 2989 NS5B 1b PRWFMLCLL 
 p423 2989 NS5B 3a TRYLLLCLL 
 
Table 2.7: HCV-specific peptides used for cross-reactivity studies 
HLA-type ID aa position protein genotype sequence 
A*02 p11 1406 NS3 1a KLVALGINAV 
 p24 1073 NS3 1a, 1b CINGVCWTV 
 p25 1073 NS3 3a TVGGVMWTV 
 p42 1406 NS3 1b KLSGLGLNAV 
 p43 1406 NS3 1b variant KLSALGLNAV 
 p47 2594 NS5B 1a ALYDVVTKL 
 p67 1273 NS3 1a, 1b GVDPNIRTGV 
 p290 1273 NS3 escape variant GVEPNIRTGV 
 p291 1073 NS3 escape variant CINGVCWSI 
 p292 1406 NS3 escape variant KLAGMGLNAV 
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HLA-type ID aa position protein genotype sequence 
A*02 p293 1406 NS3 escape variant KLVTLGINAV 
 p295 1406 NS3 escape variant KLVALGVNAV 
 p296 2594 NS5B escape variant ALYDVVSKL 
 p297 2594 NS5B escape variant ALYDVVGKL 
B*13 p32 1627 NS3 1a, 1b RLGAVQNEV 
 p33 1627 NS3 3a RLGPVQNEI 
 p366 1627 NS3 escape variant RLGPVQNET 
 p367 1627 NS3 escape variant RLGPVQNEF 
 p368 1627 NS3 escape variant RLGSVQNEI 
B*15 p146 2466 NS5B 1b SQRQKKVTF 
 p373 2466 NS5B 1a CQRQKKVTF 
 p374 2466 NS5B 3a SQRQRKVTF 
B*27 p383 840 NS2 1b ARLIWWLQY 
 p384 840 NS2 3a GRLIWWNQY 
 p387 942 NS2 3a GRWFNTYLY 
 p426 840 NS2 1a SWCLWWLQY 
 p427 942 NS2 1a GALTGTYVY 
 p428 942 NS2 1b AALTGTYVY 
 p430 840 NS2 escape variant SRIIWWNQY 
 p431 840 NS2 escape variant ARLMWWNQY 
 p432 840 NS2 3a variant GRLMWWNQY 
 p433 942 NS2 escape variant GKWFNTYLY 
 p434 942 NS2 escape variant GRWCNTYLY 
B*51 p98 1373 NS3 escape variant VPFYGKAI 
 p99 1373 NS3 1a, 1b, 3a IPFYGKAI 
 p294 1373 NS3 escape variant IPFYGKAL 
B*57 p19 2629 NS5B 1a KSKKTPMGF 
 p21 541 E2 1a NTRPPLGNW 
 p371 2629 NS5B 1b KSKKCPMGF 
 p372 2629 NS5B 3a TSKKTPLGF 
 p424 541 E2 1b NTRPPQGNW 
 p425 541 E2 3a SLRPPSGRW 
 
 
CEF Control Peptide Pool was obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH. The lyophilised peptide pool was reconstituted with 
DMSO at a concentration of 20 mg/ml per peptide and stored at -80 °C. A working 
solution was prepared at a concentration of 1 mg/ml by diluting the stock solution 
with RPMI medium without any additives. The working solution was stored at -20 °C. 
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Table 2.8: Peptides contained in CEF Control Peptide Pool 
HLA-type virus peptide sequence 
A*01 Influenza A VSDGGPNLY 
A*01 Influenza A CTELKLSDY 
A*02 Influenza M GILGFVFTL 
A*02 Influenza A FMYSDFHFI 
A*02 EBV LMP2A CLGGLLTMV 
A*02 EBV BMLF1 GLCTLVAML 
A*02:01 HCMV pp65 NLVPMVATV 
AA68 Influenza NP KTGGPIYKR 
A*03 Influenza NP RVLSFIKGTK 
A*03 Influenza A ILRGSVAHK 
A*03 EBV RVRAYTYSK 
A*03 EBV RLRAEAQVK 
A*03, A*11, A*60:81 Influenza M SIIPSGPLK 
A*11 EBV EBNA 4NP AVFDRKSDAK 
A*11 EBV IVTDFSVIK 
A*11 EBV ATIGTAMYK 
A*24 EBV RTA DYCNVLNKEF 
B*07 Influenza NP LPFDKTTVM 
B*07 EBV RPPIFIRRL 
B*08 Influenza NP ELRSRYWAI 
B*08 EBV B2LF-1 RAKFKQLL 
B*08 EBV EBNA 3A FLRGRAYGL 
B*08 EBV EBNA 3 QAKWRLQTL 
B*18 HCMV SDEEEAIVAYTL 
B*27 Influenza NP SRYWAIRTR 
B*27 Influenza M ASCMGLIY 
B*27 EBV EBNA 3C RRIYDLIEL 
Peptides indicated in bold were also purchased as single peptides from peptides&elephants. 
 
2.9 Patients 
Blood samples from PWID were collected from the ward for inpatient detoxification 
treatment of drug addicts or the clinic for opioid maintenance treatment (OMT) at the 
Department of Addictive Behaviour and Addiction Medicine, Rhine State Hospital 
Essen, Hospital of the University of Duisburg-Essen. In total 363 blood samples were 
collected. 40 samples were seronegative for HCV antibody (by anti-HCV CMIA from 
Abbott), while 323 patients were HCV antibody positive, including 91 HCV-RNA 
negative patients, 120 with genotype 1, 98 with genotype 3 and 14 infected with other 
genotypes. HCV viral load was determined with the Versant HCV RNA 3.0 (bDNA) 
assay with a detection limit 615 international units (IU)/ml and further tested in a 
qualitative Versant assay (TMA) with a detection limit of 10 IU/ml. Patients without 
detectable HCV-RNA who had previously received antiviral therapy for HCV were 
excluded from this study. Written informed consent was obtained from all patients 
and the study was approved by the local ethics committee. 
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In addition, plasma samples from eleven HLA-B*27 positive individuals with chronic 
HCV genotype 3a infection who presented to the University Hospital of Freiburg were 
included in the sequence analysis of HLA-B*27 positive patients. Samples were 
kindly provided by Christoph Neumann-Haefelin, Department of Medicine II, 
University of Freiburg, Freiburg, Germany. 
 
2.10 Consumables and equipment 
Cell culture flasks (T25, T75) Greiner Bio-One 
Cell culture plates, flat bottom (6-, 12-, 24-, 48-, 96-well) Greiner Bio-One 
Centrifuge 5415 R Eppendorf 
Centrifuge 5424 Eppendorf 
Cryo tubes, 2.0 mL   Greiner Bio-One 
FACS Calibur  Becton Dickinson 
FACS Canto II Becton Dickinson 
KX-21N Sysmex 
LeucosepTM tubes, 50 mL Greiner Bio-One 
Lightcycler 2.0 Roche 
Mastercycler gradient Eppendorf 
Mastercycler personal Eppendorf 
MJ Mini BIO RAD 
Megafuge 1.0R Heraeus 
Megafuge 40R Thermo Scientific 
Microscope Primo Vert Zeiss 
Microscope TMS Nikon 
Mr. Frosty freezing container  Thermo Scientific 
Navios Beckman Coulter 
NanoDrop Thermo Scientific 
Polystyrene round-bottom tubes, 5 mL   BD Falcon 
Thermomixer comfort Eppendorf 
Thermostat plus Eppendorf 
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2.11 Software and webpages 
Allele Frequency Net Database http://www.allelefrequencies.net 
CodonCode Aligner 4.2.5 CodonCode Corporation 
FlowJo 10.0.7 Tree Star Inc. 
Geneious 7.0.6 Biomatters Ltd. 
Graph Pad Prism 5 GraphPad Software, Inc. 
HCV sequence database (Kuiken et al., 2005) http://hcv.lanl.gov/content/index 
MHC-I Binding Prediction Tool http://tools.immuneepitope.org/mhci 
Microsoft Office 2008 for Mac Microsoft Corporation 
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3 Methods 
3.1 Immunological methods 
3.1.1 Isolation and cryopreservtion of perihpherial blood mononuclear cells 
(PBMCs) 
PBMCs were isolated from peripheral blood samples via Ficoll density centrifugation 
(Böyum, 1968). Briefly, 15 ml of Biocoll separating solution were pipetted into a 50 ml 
Leucosep tube and centrifuged for 1 min at 491 x g in order to allow the Biocoll to 
pass through the filter inside the tube. Subsequently, 30 ml of blood were added to 
the tube and centrifuged for 10 min at 1055 x g. Due to the different densities of the 
cell types present in blood, separation into different layers occurs during 
centrifugation. Red blood cells and granulocytes aggregate at the bottom of the tube 
below the filter, while lymphocytes, monocytes and platelets are not dense enough to 
penetrate the Biocoll layer and accumulate at the interphase above the filter. The 
layer containing the lymphocytes was then transferred into a new 50 ml Falcon tube 
and centrifuged at 872 x g for 8 min. The cells were washed twice with 40 ml PBS in 
order to remove platelets. During the second washing step 200 µl of PBMCs were 
removed. The cells were pelleted and frozen at -20°C for later DNA extraction (see 
3.2.1). Afterwards cells were resuspended in freezing medium and placed into a Mr. 
Frosty freezing container, which was placed at -80 °C. After one day the PBMCs 
were transferred into liquid nitrogen. 
 
3.1.2 Thawing of PBMCs 
PBMCs were thawed in a 37 °C water bath and transferred into a 15 ml Falcon tube 
containing 9 ml of PBS. The cells were then centrifuged at 706 x g for 6 min. 
Afterwards the supernatant was discarded and the cells were washed with 10 ml of 
PBS. The total cell number was determined using the KX-21N cell counter.  
 
3.1.3 Expansion of HCV-specific CD8+ T cells for intracellular cytokine 
staining (ICS) 
After thawing PBMCs were resuspended at a concentration of 2x106 cells/ml in R10 
medium containing 25 U/ml recombinant IL-2 and 0.1 µg/ml anti-CD28 and anti-
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CD49d. Depending on the experiment, the cells were then stimulated with different 
HCV-specific peptides (1 µg/ml per peptide). As a positive control one well containing 
2 x 106 cells was stimulated with CEF Peptide Control Pool. PBMCs were incubated  
at 37 °C in a humidified atmosphere containing 5% CO2. After 7 days half the total 
volume of the culture medium containing IL-2 was added. 
 
3.1.4 Analysis of the HCV-specific CD8+ T cell response against HLA-matched 
peptide pools by ICS 
On day 10 after stimulation with HLA-matched peptide pools (see table 2.5) aliquots 
of 1-2 x 105 cells were transferred into 96 well round bottom plates, washed twice 
with R10 medium and then restimulated with the same peptide pools (10 µg/ml per 
peptide) for 4 h in the presence of BFA (100 ng/ml). One well was left unstimulated 
(no peptide) as a negative control. The BFA was used to prevent transport of 
intracellular vesicles continaing e.g. IFN-γ from the ER to the cell surface, thereby 
facilitating the later intracellular detection of IFN-γ. Subsequently, the PBMCs were 
pelleted at 491 x g for 5 min and washed once with PBS containing 1% FBS 
(PBS/FBS). The cells were then stained with antibodies against the surface antigens 
CD4 and CD8 (CD4 PE and CD8 APC) in a total volume of 100 µl of PBS/FBS for 10 
min at 4 °C. After another washing step with PBS/FBS, the PBMCs were fixed for 15 
min at 4 °C using IC fixation buffer. Following two washing steps with 1x 
Permeabilization Buffer, the cells were intracellularly stained for IFN-γ (IFN-γ FITC) in 
100 µl of 1x Permeabilization Buffer for 20 min at 4 °C. After another washing step 
with PBS the cells were resuspended in 200 µl of PBS, transferred into 5 ml round-
bottom tubes and acquired either on a FACSCalibur running CellQuest software or 
on a Navios. Analysis of expression patterns was done using FlowJo. 
CD8+ T cell responses were counted as positive, if the percentage of CD8+IFN-γ+ T 
cells was at least twice as high in the peptide stimulated sample as in the 
unstimulated control sample after subtraction of the background. If positive 
responses were detected, the experiment was repeated the following day using the 
corresponding single peptides contained in the positive HLA-matched pool to 
determine against which peptide the CD8+ T cell response was directed.  
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3.1.5 Analysis of the CD8+ T cell response against putative novel HLA-B*27 
restricted epitopes by ICS 
In order to discover potential new HLA-B*27 restricted epitopes, the consensus 
sequence of all GT1a, GT1b or GT3a sequences available in the HCV sequence 
database (see table 4.1) were entered into the MHC-I Binding Predictions Tool 
(http://tools.immuneepitope.org/mhci). The MHC class I binding predictions were 
made using the IEDB analysis resource Consensus tool (Kim et al., 2012) which 
combines predictions from ANN aka NetMHC (3.4) (Lundegaard et al., 2008; Nielsen 
et al., 2003), SMM (Peters and Sette, 2005) and Comblib (Sidney et al., 2008). All 
9mers that had a percentile rank score ≤1 for binding to the HLA-B*27:05 molecule 
were ordered from peptides&elephants and used for further analysis. In addition, 
known HLA-B*27 restricted peptides were also included in the analysis. 
After thawing (see 3.1.2) and expansion (see 3.1.3) of PBMCs from HLA-B*27 
positive PWID, the cells were stimulated with HLA-B*27 restricted peptides (see table 
2.6) for 10 days. ICS staining for IFN-γ was done essentially as described above (see 
3.1.4), but before staining for surface molecules the PBMCs were stained with 
Fixable Viability Dye eFluor780 for 15 min at 4 °C to exclude dead cells. In addition, 
CD3 PerCP-Cy5.5 was included in the surface stain master mix to exclude non-T 
cells from further analysis steps. All samples were acquired on a FACSCanto II 
running FACSDiva software and further analysed using FlowJo. 
 
3.1.6 Ex vivo analysis of HLA-B*27 restricted HCV-specific CD8+ T cells via 
MHC-class I dextramer staining 
PBMCs from 25 HLA-B*27 positive PWID were stained directly after thawing and 
after 7 days of peptide-specific expansion to determine the frequency of HCV-specific 
CD8+ T cells directed against three different HLA-B*27 restricted epitopes. For this 
purpose, 2-3x106 cells per patient were transferred into one well on a 96-well round 
bottom plate and washed once with PBS. The cells were first stained with Fixable 
Viability Dye eFluor506 for 15 min at 4 °C to exclude dead cells. Subsequently, the 
PBMCs were stained with 10 µl of MHC class dextramer (p20 labelled with FITC, 
p384 labelled with PE and p387 labelled with APC) that had been diluted 1:5 with 
PBS/FBS for 10 min at 4 °C. After another washing step antibodies against CD3 
labelled with PerCP-Cy5.5, CD4 labelled with APC-eFluor780, CD8 labelled with 
eFluor450 and the memory marker CD127 labelled with PE-Cy7 were added and the 
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cells were incubated for 15 min at 4 °C. After fixation the cells were washed and then 
acquired on a FACSCanto II running FACSDiva software and further analysed using 
FlowJo. Dextramer responses were counted as positive if they constituted at least 
0.004% of the total CD8+ T cell population and a distinct population could be 
identified. 
 
3.1.7 Analysis of the cross-reactivity of CD8+ T cells against several sequence 
variants of the same epitope 
After expansion of PBMCs with different variants of the same epitope in different 
wells for 10 days, the cells were separately restimulated with the peptide used for 
expansion as well as the variants of the same epitope that should be analysed for 
cross-reactivity for 4 h. Subsequently, an ICS for the production of IFN-γ was 
performed as described in 3.1.5. 
 
3.1.8 Analysis of the TCR Vβ repertoire in HCV-specific CD8+ T cells 
In order to analyse the TCR Vβ chain usage of HCV-specific CD8+ T cells, PBMCs 
were expanded in the presence of HCV-specific peptides. After 11 days 1-2 x 105 
cells were restimulated with the same peptides (10 µg/ml) for 4 h in the presence of 
BFA. One well was left unstimulated (no peptide) as a negative control. Afterwards 
the cells were washed with PBS and stained with Fixable Viability Dye eFluor506 for 
15 min at 4 °C to exclude dead cells. After another washing step, the PBMCs were 
stained with antibodies against all surface antigens (the 9 TCR Vβ pools (table 2.2), 
CD4 APC-eFluor780 and CD8 eFluor450 (for pool 4 CD8 APC was used instead)) for 
10 min at 4 °C. After fixation and permeabilization, the cells were additionally stained 
with antibodies against IFN-γ labelled with PE-Cy7. All samples were acquired on a 
FACSCanto II running FACSDiva software and further analysed using FlowJo. 
 
 
3.1.9 Phenotypical analysis of HCV-specific CD8+ T cells via dextramer 
staining 
HCV-specific CD8+ T cells from 24 PWID who exhibited HCV-specific CD8+ T cell 
responses during the screen with HLA-matched peptides (see 3.1.4) were stained 
directly after thawing and after 7 days of peptide-specific expansion. For each patient 
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stainings were performed that included antibodies against Bim in addition to 
antibodies against CD8, CD38 and MHC class I dextramer. Thus, after thawing 1x106 
cells were transferred into two wells on a 96-well round bottom plate and washed 
once with PBS/FBS. The PBMCs were then stained with 10 µl of MHC class 
dextramer that had been diluted 1:10 with PBS/FBS for 10 min at room temperature 
in the dark. After another washing step antibodies against CD8 labelled with 
PerCP-Cy5.5 and the activation marker CD38 labelled with APC were added and the 
cells were incubated for 15 min at 4 °C. Following fixation and permeabilization, the 
cells were stained with 10 µl of antibody directed against the pro-apoptotic marker 
Bim, which was diluted 1:10 with Permeabilization buffer, for 30 min at room 
temperature in the dark. Subsequently, an antibody against IgG2a labelled with FITC 
was added as a secondary antibody against the Bim antibody to be able to detect it 
by flow cytometry. The PBMCs were again incubated for 30 min at room temperature 
in the dark and then acquired either on a FACSCalibur running CellQuest software or 
on a Navios and further analysed using FlowJo. 
 
3.2 Molecular biology methods 
3.2.1 Isolation of DNA from PBMCs 
Genomic DNA was extracted from PBMCs using the QIAamp Blood Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. In short, pelleted 
PBMCs were thawed (aliquoted during washing steps in 3.1.1) and resuspended in 
200 µl of PBS. Subsequently, 20 µl of QIAGEN protease and 200 µl of AL buffer 
were added and the mixture was pulse vortexed for 15 s. After 10 min of incubation 
at 56 °C, 200 µl of ethanol were added, the whole sample was transferred into a 
QIAamp Mini Spin Column and centrifuged for 1 min at 5939 xg. The flow through 
was discarded and the column was placed in a new 2 ml collection tube before 
adding 500 µl of AW1 buffer and centrifuging for 1 min at 5939 xg. After discarding 
the flow through, the column was washed with 500 µl of AW2 buffer and centrifuged 
for 3 min at 18188 xg. The column was then placed in a new collection tube and 
centrifuged for 1 min at 18188 xg in order to remove excess liquid. DNA was eluted 
from the column by addition of 50 µl of distilled water and incubation for 1 min at 
room temperature. The last step was repeated once so that DNA was eluted in a total 
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volume of 100 µl. The DNA concentration was determined via NanoDrop 
measurement. 
 
3.2.2 Analysis of the IFNL3 genotype 
IFNL3 rs12979860 genotyping was performed using the LightSNiP Typing Assay 
rs12979860 Homo sapiens and the LightCycler FastStart DNA MasterPLUS HybProbe 
PCR Kit on a LightCycler 2.0 Instrument. The amplification protocol consisted of an 
initial denaturation step of 95°C for 10 min followed by 45 cycles of 95°C for 10s, 
60°C for 10s and 72°C for 15s and subsequent melting curve analysis. Analysis of 
the IFNL3 genotype distribution between different HCV infection outcomes was 
performed using Fisher’s exact test. 
 
3.2.3 Analysis of the HLA-type 
HLA-A and HLA-B typing at two-digits resolution-level was performed using 
sequence-specific primers (PCR-SSP) methodology or alternatively using sequence-
specific oligonucleotides (LABType methodology, both provided by One Lambda Inc., 
Canoga Park, CA, USA) at the Institute for Transfusion Medicine, University Hospital 
Essen, Essen, Germany (Oudshoorn et al., 2007).  
Analysis of the HLA type distribution between different HCV infection outcomes was 
performed using Fisher’s exact test or Chi-square test (depending on group size). 
Significant or borderline significant results were further tested via logistic regression 
analysis to avoid false positive results at the Department of Bioinformatics, University 
of Duisburg-Essen, Essen, Germany. 
 
3.2.4 Analysis of the epitope-specific avidities to the HLA-B*27:05 molecule  
Peptide binding studies were performed at the Sanquin Company in Amsterdam, the 
Netherlands. Binding of different peptides to the HLA-B*27:05 MHC class I-molecules 
was tested via UV-induced peptide-exchange reactions whose efficiency were 
determined by HLA class I ELISA. In brief, a UV-labile peptide was used to stabilize 
the HLA class I molecules to form the whole complex. Through UV irradiation at 366 
nm in the presence of the peptide of interest, the UV-labile peptide is cleaved and 
can be exchanged for the peptide of interest yielding an HLA class I complex with the  
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peptide of choice. If a peptide with a low binding affinity is used for the exchange, the 
complex will quickly disintegrate, while a peptide with a high binding affinity will 
stabilize the complex (Toebes et al., 2006). This procedure was followed by an HLA 
class I ELISA, that can only detect intact HLA class I complexes, as the capture of 
the HLA class I molecule is performed via the α-chain of the HLA class I molecule, 
while the detection antibody is directed towards the β2-microglobulin. A peptide that 
binds with high affinity to HLA-B*27:05 was used as positive control. 
 
3.2.5 Isolation of viral RNA from plasma samples 
HCV viral RNA was extracted from PWID plasma samples using the QIAamp Viral 
RNA Mini Kit. In short, 140 µl of patient plasma were mixed with 560 µl of AVL 
buffer/carrier RNA that had been preheated to 80 °C. The mixture was incubated at 
room temperature for 10 min before 560 µl of ethanol were added. After 15 s of 
vortexing, 630 µl were transferred into a QIAamp Mini column and centrifuged at 
5939 xg for 1 min. The flow through was discarded and the previous step was 
repeated for the remaining 630 µl. After each of the following steps a new collection 
tube was used.  The column was washed twice, once with 500 µl of AW1 buffer and 
once with 500 µl of AW2 buffer before eluting the RNA into a new Eppendorf tube 
with 60 µl of AVE buffer. The RNA was then stored in two aliquots of 30 µl at -80 °C 
until further use. 
 
3.2.6 Qualitative RT-PCR 
To analyse the autologous viral sequence of chronically HCV infected PWID, the 
NS2, NS3 or NS5B fragments of different patients was amplified using a combined 
RT- and nested PCR approach. For this purpose 5 µl of viral RNA isolated from 
patient plasma (see 3.2.5) were used for transcription into complementary DNA 
(cDNA) and then directly amplified using the Qiagen OneStep RT-PCR Kit according 
to the manufacturer’s instructions. The master mix used for RT-PCR is shown in 
table 3.1 and the amplification protocols in table 3.2 and table 3.3. The reaction was 
performed in a total volume of 25 µl. Primer combinations for all PCR steps are 
shown in table 2.4. 
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Table 3.1: Master mix for RT-PCR 
component volume  
RNAse-free water 11 µl 
5x OneStep RT-PCR Buffer 5 µl 
dNTP Mix, 10 mM each 1 µl 
F-primer 1 µl 
R-primer 1 µl 
QIAGEN OneStep RT-PCR Enzyme Mix (Omniscript Reverse 
Transcriptase, Sensiscript Reverse Transcriptase, and HotStarTaq DNA 
Polymerase ) 
1 µl 
RNA template 5 µl 
 
Table 3.2: Amplification protocol for RT-PCR of NS2 and NS3 fragments 
   
 
 
    
 
 
 
Table 3.3: Amplification protocol for RT-PCR of NS5B fragment 
   
 
 
    
 
 
 
The resulting PCR products were then further amplified in a second nested PCR 
step. The master mix and amplification protocol are shown in table 3.4, 3.5 and 3.6, 
respectively. The reaction was performed in a total volume of 50 µl. 
 
 
 
 
 
 
step temperature duration cycles 
reverse transcription 50 °C 30.0 min 1 
initial PCR activation step 95 °C 15.0 min 1 
denaturation 94 °C 0.5 min 
35 annealing 54 °C 0.5 min 
elongation 72 °C 2.5 min 
final elongation 72 °C 20.0 min 1 
step temperature duration cycles 
reverse transcription 50 °C 30.0 min 1 
initial PCR activation step 95 °C 15.0 min 1 
denaturation 94 °C 0.5 min 
35 annealing 54 °C 0.5 min 
elongation 72 °C 2 min 
final elongation 72 °C 20.0 min 1 
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Table 3.4: Master mix for nested PCR 
component volume  
aqua dest. 29 µl 
5x Green GoTaq Flexi Buffer (containing mM MgCL2) 14 µl 
dNTP Mix, 10 mM each 1 µl 
F-primer 1 µl 
R-primer 1 µl 
GoTaq Flexi DNA Polymerase 1 µl 
PCR product 3 µl 
 
Table 3.5: Amplification protocol for nested PCR of NS2 and NS3 fragments 
   
 
 
    
 
 
Table 3.6: Amplification protocol for nested PCR of NS5B fragment 
   
 
 
 
 
 
To verify the amplification of fragments of the correct size, 2 µl of PCR product were 
applied to a 1.2% agarose gel and gel electrophoresis was performed at 100 V for 
30 min. 
 
3.2.7 HCV sequence analysis 
HCV PCR fragments (3 µl) were mixed with 9 µl of aqua dest. and 2 µl of either 
forward, reverse or one of the internal primers and send to LGC genomics for 
sequencing. HCV sequence analysis was performed using CodonCode Aligner or 
Geneious. 
 
step temperature duration cycles 
initial denaturation 95 °C 2.0 min 1 
denaturation 94 °C 0.5 min 
35 annealing 54 °C 0.5 min 
elongation 72 °C 2.0 min 
final elongation 72 °C 20.0 min 1 
step temperature duration cycles 
initial denaturation 95 °C 2.0 min 1 
denaturation 94 °C 0.5 min 
35 annealing 56 °C 0.5 min 
elongation 72 °C 1.0 min 
final elongation 72 °C 20.0 min 1 
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4 Results 
4.1 PWID cohort  
Injection drug use is the most common risk factor for HCV infection in Germany and 
other developed countries (Cornberg et al., 2011). Here we work with a cohort of 363 
PWID who were recruited from the ward for inpatient detoxification treatment of drug 
addicts or the clinic for OMT at the Department of Addictive Behaviour and Addiction 
Medicine, Rhine State Hospital Essen, Hospital of the University of Duisburg-Essen. 
Approximately 90% of patients were HCV antibody positive, including 232 patients 
(64%) with detectable HCV RNA and 91 RNA negative patients (25%) (table 4.1).  
While there were no significant differences in either the viral load or the ratio between 
male and female patients, the age of the subjects differed considerably between the 
subgroups. Seronegative patients were significantly younger than either chronically 
GT1 infected patients or patients with undetectable RNA levels. 
 
Table 4.1: PWID patient characteristics 
 total GT 1 GT 3 other  GT RNA neg SN p-values 
number of subjects 
(% of total) 
363 
(100.0) 
120 
(33.1) 
98 
(27.0) 
14 
(3.9) 
91 
(25.1) 
40 
(11.0) - 
age in years, mean 
(SD) 
37.5 
(8.7) 
39.3 
(10.1) 
36.4 
(7.6) 
39.9 
(9.1) 
38.0 
(7.3) 
32.5 
(8.0) 
GT1 vs. SN: *** 
RNA neg vs. SN: ** 
male/female 277/86 90/30 71/27 12/2 73/18 31/9 - 
viral load in kIU/ml, 
median 451.9 675.2 236.8 506.5 - - - 
viral load in kIU/ml, 
interquartile range 
75.2- 
1536.0 
83.2-
1867.0 
64.3-
1284.0 
120.4- 
975.1 - - - 
GT: genotype, SN: seronegative, SD: standard deviation, IU: international units 
 
The distribution of HCV genotypes was quite heterogeneous with GT1 and GT3 
being the predominant infecting genotypes (33.1% and 27.0% of the total cohort, 
respectively) (table 4.1). When the cohort was further subdivided into male and 
female patients within the chronically infected subgroup, it became evident that HCV 
genotype distribution was very similar between male and female infected patients 
(figure 4.1). No significant differences between the sexes could be found for the 
individual genotypes (p-values were calculated using Fisher’s exact test), even 
though there was a slight trend towards more GT1a infection in male patients and 
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more GT1b and GT3a infection in female patients. Interestingly, GT4 infection 
occurred only in male patients. 
 
 
Figure 4.1: Genotype distribution 
Genotype distribution within the chronic PWID subgroup according to sex. 
 
4.2 Genetic host factors and their influence on HCV infection outcome 
As host genetic factors are known to play an important role during viral infections in 
general and also HCV infection in particular, we wanted to investigate what role 
genetic host factors play in determining the outcome of HCV infection. Here, we were 
particularly interested in potential differences between GT1 and GT3 infections. 
 
4.2.1 IFNL3 genotype  
Genome-wide association studies have identified single nucleotide polymorphisms 
on chromosome 19q13.13 near the IFNL3 gene (formerly known as IL28B), which 
encodes for IFN-λ3, that are strongly associated with both spontaneous clearance of 
HCV (Thomas et al., 2009) as well as improved response to antiviral therapy with 
IFN-α during GT1 infection (Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 
2009). The precise mechanism behind these associations has not yet been 
completely elucidated.  
As a first step, it was tested whether the association of the IFNL3 rs12979860 C/C 
genotype with spontaneous clearance could be reproduced in the PWID cohort. For 
this purpose, the IFNL3 rs12979860 genotype was determined in a subgroup of 249 
seropositive PWID, including 73 patients with undetectable RNA levels and 176 
chronically infected patients. The “protective” IFNL3 rs12979860 C/C genotype was 
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significantly less frequent in GT1 infected patients compared to patients with resolved 
HCV infection (46.6% vs. 57.5%, p=0.0056; figure 4.2). Subjects infected with GT3 
showed an intermediate IFNL3 C/C genotype frequency of 50%. 
 
Figure 4.2: Frequency of the IFNL3 C/C genotype according to infection outcome 
The frequency of the rs12979860 C/C genotype in the total cohort and in different subgroups. p-values 
were calculated using Fisher’s exact test.  
  
4.2.2 HLA class I alleles 
As a second host factor, we examined the influence of the HLA class I type A and B 
genotype on the outcome of HCV infection in the PWID cohort. DNA from PWID was 
typed at two-digit resolution level and compared to data from the general German 
population that was obtained from the German bone marrow registry via 
allelefrequencies.net (population: Germany, n=11407) (Gonzalez-Galarza et al., 
2011).  
No data was available about the infecting genotype in patients with spontaneously 
resolved HCV infection, but the frequency of GT1 and GT3 infection was very similar 
in the overall cohort (see table 4.1). Therefore, the following comparisons were 
performed based on the assumption that a similar frequency of both genotypes in the 
chronic subgroup of the cohort would also indicate a similar frequency of patients 
who had resolved either GT1 or GT3 infection in the HCV RNA negative subgroup of 
the cohort. 
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Table 4.2: HLA class I allele frequencies of PWID cohort 
HLA-allele German population+ PWID cohort GT1 GT3 RNA neg GT1 vs. RNA neg GT3 vs. RNA neg 
 % % # % # % # % p-value* OR 95%CI p-value OR 95%CI 
A*01 15.0 13.9 40 16.7 21 10.7 25 13.7 0.409 1.26 0.73-2.16 0.369 0.75 0.41-1.40 
A*02 29.2 33.7 78 32.5 74 37.8 56 30.8 0.705 1.08 0.72-1.64 0.153 1.36 0.89-2.09 
A*03 15.5 14.4 37 15.4 24 12.2 28 15.4 0.993 1.00 0.59-1.71 0.376 0.77 0.43-1.38 
A*11 5.1 5.0 10 4.2 14 7.1 7 3.8 0.868 1.09 0.41-2.91 0.162 1.92 0.76-4.88 
A*23 2.4 1.6 4 1.7 3 1.5 3 1.6 1.000 1.01 0.22-4.58 1.000 0.93 0.18-4.65 
A*24 9.5 8.1 15 6.3 18 9.2 17 9.3 0.235 0.65 0.31-1.33 0.958 0.98 0.49-1.97 
A*25 2.3 2.9 10 4.2 6 3.1 2 1.1 0.077 3.91 0.85-18.08 0.287 2.84 0.57-14.27 
A*26 3.4 2.6 4 1.7 8 4.1 4 2.2 0.731 0.75 0.19-3.06 0.384 1.89 0.56-6.40 
A*29 2.7 2.1 8 3.3 0 0.0 5 2.7 0.730 1.22 0.39-3.80 0.025 0.00 n.a. 
A*30 2.3 2.6 5 2.1 5 2.6 6 3.3 0.438 0.62 0.19-2.08 0.666 0.77 0.23-2.56 
A*31 2.3 1.9 3 1.3 3 1.5 6 3.3 0.183 0.37 0.09-1.51 0.323 0.46 0.11-1.85 
A*32 3.8 3.9 12 5.0 6 3.1 6 3.3 0.391 1.54 0.57-4.19 0.896 0.93 0.29-2.93 
A*33 1.3 1.5 1 0.4 5 2.6 3 1.6 0.320 0.25 0.03-2.42 0.725 1.56 0.37-6.63 
A*66 0.4 0.6 1 0.4 1 0.5 2 1.1 0.580 0.38 0.03-4.19 0.611 0.46 0.04-5.13 
A*68 4.1 5.2 12 5.0 8 4.1 12 6.6 0.484 0.75 0.33-1.7 0.276 0.60 0.24-1.51 
B*07 13.1 13.4 35 14.6 27 13.8 21 11.5 0.361 1.31 0.73-2.34 0.514 1.22 0.67-2.25 
B*08 10.0 9.1 30 12.5 15 7.7 11 6.0 0.027 2.22 1.08-4.56 0.537 1.29 0.58-2.88 
B*12 0.0 0.2 0 0.0 0 0.0 1 0.5 0.431 0.00 n.a. 0.481 0.00 n.a. 
B*13 3.2 4.7 8 3.3 11 5.6 10 5.5 0.277 0.59 0.23-1.53 0.960 1.02 0.42-2.47 
B*14 2.5 1.6 2 0.8 5 2.6 3 1.6 0.656 0.50 0.08-3.03 0.725 1.56 0.37-6.63 
B*15 8.0 8.7 28 11.7 13 6.6 13 7.1 0.120 1.72 0.86-3.42 0.845 0.92 0.42-2.05 
B*18 4.6 4.9 9 3.8 14 7.1 7 3.8 0.959 0.97 0.36-2.67 0.162 1.92 0.76-4.88 
B*27 4.3 4.7 8 3.3 5 2.5 16 8.8 0.030 0.36 0.15-0.86 0.010 0.27 0.10-0.76 
B*35 10.0 11.3 24 10.0 25 12.8 21 11.5 0.612 0.85 0.46-1.58 0.718 1.12 0.6-2.08 
B*37 1.5 0.6 1 0.4 2 1.0 1 0.5 1.000 0.76 0.05-12.19 1.000 1.87 0.17-20.76 
B*38 2.2 1.6 3 1.3 5 2.6 2 1.1 1.000 1.14 0.19-6.89 0.451 2.36 0.45-12.3 
B*39 2.0 2.8 5 2.1 6 3.1 6 3.3 0.438 0.62 0.19-2.08 0.896 0.93 0.29-2.93 
B*40 6.6 7.9 19 7.9 16 8.2 14 7.7 0.932 1.03 0.5-2.12 0.866 1.07 0.51-2.25 
B*41 0.9 1.9 2 0.8 4 2.0 6 3.3 0.081 0.25 0.05-1.24 0.531 0.61 0.17-2.2 
B*44 12.8 10.5 25 10.4 17 8.7 23 12.6 0.477 0.80 0.44-1.47 0.211 0.66 0.34-1.27 
B*45 0.6 0.2 1 0.4 0 0.0 1 0.0 1.000 0.76 0.05-12.19 1.000 0.00 n.a. 
B*47 0.4 0.2 1 0.4 0 0.0 1 0.0 1.000 0.76 0.05-12.19 1.000 0.00 n.a. 
B*48 0.1 0.2 0 0.0 0 0.0 1 0.5 0.431 0.00 n.a. 0.481 0.00 n.a. 
B*49 1.4 0.5 1 0.4 0 0.0 2 1.1 0.580 0.38 0.03-4.19 0.231 0.00 n.a. 
B*50 1.3 0.6 2 0.8 0 0.0 2 1.1 1.000 0.76 0.11-5.42 0.231 0.00 n.a. 
B*51 6.2 7.1 16 6.7 17 8.7 11 6.0 0.796 1.11 0.5-2.45 0.329 1.48 0.67-3.24 
B*52 0.9 1.1 3 1.3 1 0.5 3 1.6 1.000 0.76 0.15-3.79 0.355 0.31 0.03-2.97 
B*55 1.4 1.8 6 2.5 4 2.0 1 0.5 0.247 4.64 0.55-38.89 0.373 3.77 0.42-34.06 
B*56 0.9 0.3 2 0.8 0 0.0 0 0.0 0.508 n.a. n.a. 1.000 n.a. n.a. 
B*57 3.6 3.4 8 3.3 6 3.1 7 3.8 0.778 0.86 0.31-2.42 0.676 0.79 0.26-2.39 
B*58 1.1 0.6 0 0.0 4 2.0 0 0.0 1.000 n.a. n.a. 0.124 n.a. n.a. 
+ The HLA class I allele frequencies were obtained from allelefrequencies.net and include 11407 individuals from the German 
bone marrow registry; *p-values were calculated using either χ² or Fisher’s exact test depending on group size, significant 
values are marked in red; OR: odds ratio; CI: confidence interval; n.a.: not applicable 
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The distributions of HLA-alleles between the general German population and the 
PWID cohort were very similar and no significant differences could be found 
(table 4.2). A comparison of the HLA-allele frequencies within the PWID cohort 
between chronically GT1 or GT3 infected patients and patients with resolved 
infection only showed significant differences for three HLA class I alleles.  
The frequency of HLA-A*29 was decreased in patients with GT3 infection compared 
to patients with resolved infection (0.0% vs. 2.7%, p=0.025). HLA-B*08 was 
significantly more common in GT1 infected patients than in patients with resolved 
infection (12.5% vs. 6.0%, p=0.027), while HLA-B*27 was significantly enriched in 
patients with resolved infection (8.8%) compared to both GT1 (3.8%) and GT3 (2.0%) 
infected patients (p=0.030 and p=0.010, respectively).  
In order to avoid false positive results due to either too small group sizes or too many 
simultaneous comparisons, multiple logistic regression analysis was performed in 
cooperation with the Department of Bioinformatics, University of Duisburg-Essen, 
Essen (table 4.3). The increased frequency of HLA-B*08 in GT1 infected patients 
compared to patients with resolved infection could be confirmed in this analysis 
(p=0.037). HLA-B*27 was also still significantly more common in patients with 
resolved infection compared to patients with GT3 infection (p=0.008), while this allele 
was only borderline enriched compared to GT1 (p=0.063) according to this analysis. 
The increased frequency of HLA-A*29 in resolved patients compared to GT3 infected 
patients was calculated as non-significant (p=1.000), indicating a false positive result 
during the first analysis. 
 
Table 4.3: Multiple logistic regression analysis of HLA class I alleles associated with 
viral clearance 
 GT1 vs. RNA neg GT3 vs RNA neg 
HLA-allele p-value OR 95% CI p-value OR 95% CI 
A*29    1.000 0.00  
B*08 0.037 2.22 1.08-4.56    
B*27 0.063 0.4 0.17-0.94 0.008 0.22 0.07-0.66 
 
Overall, these findings seem to indicate that HLA-B*08 has a detrimental effect 
during HCV GT1 infection, whereas HLA-B*27 seems to be protective against both 
GT1 and GT3 infection. The protective effect during GT3 infection was unexpected, 
as the known immunodominant HLA-B*27-restricted epitope is only present in GT1 
(Neumann-Haefelin et al., 2006, 2010). 
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4.2.3 Influence of genetic host factors on the HCV-specific CD8+ T cell 
response 
As we could show that some genetic host factors like the IFNL3 rs12979860 C/C 
genotype and HLA-B*27 are correlated with spontaneous clearance of HCV infection 
in our PWID cohort, we next tried to elucidate the mechanisms behind theses 
associations in more detail.  
While the protective effect of certain HLA class I alleles is almost certainly associated 
with specific CD8+ T cell responses against HCV, there also might be a link to CD8+ 
T cell immunity in the case of the IFNL3 genotype. The C/C genotype has been 
associated with more symptomatic hepatitis and jaundice and thereby increased 
cytotoxic activity in the liver that is likely to be caused by cytotoxic CD8+ T cells 
(Beinhardt et al., 2012; Tillmann et al., 2010). For HLA-B*27 it has been shown that 
the protective effect is associated with the immunodominant CD8+ T cell epitope 
NS5B2841 ARMILMTHF (Neumann-Haefelin et al., 2010). We therefore wanted to see 
whether the IFNL3 genotype and the HLA-B*27 status of the patient has any 
influence on the CD8+ T cell response. 
For this purpose, magnitude and breadth of the CD8+ T cell response in 115 PWID 
was determined via IFN-γ staining after expansion and restimulation with previously 
described optimal peptides (see table 2.5). For each patient only the peptides 
matching the patient’s HLA-type were tested. 
 
 
Figure 4.3: Magnitude and breadth of the CD8+ T cell response according to infection 
outcome  
A The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of 
HLA-matched peptides is shown. Each symbol represents the CD8+ T cell response to one peptide.   
B The percentage of reactive peptides of all tested HLA-matched peptides is shown for each 
individual. Horizontal lines indicate the mean. p-values were calculated using the Kruskal-Wallis test 
(**: p<0.01, ***: p<0.001). 
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The magnitude of the CD8+ T cell response as measured by the percentage of 
CD8+IFN-γ+ T cells directed against each peptide was significantly increased in 
patients with resolved HCV infection compared to patients with either GT1 or GT3 
infection (figure 4.3A). Additionally, the percentage of reactive peptides of all tested 
HLA-matched peptides for each individual was used as an indicator of the breadth of 
the CD8+ T cell response. Although there was also a trend towards a greater breadth 
of the CD8+ T cell response in PWID with spontaneously resolved HCV infection, this 
trend was not statistically significant (figure 4.3B). Interestingly, the breadth and 
magnitude of the CD8+ T cell response was nearly identical in the two genotypes 
even though the peptides used for detection were biased toward the GT1 sequence. 
To test whether the CD8+ T cell response was influenced by the IFNL3 genotype, the 
data on the magnitude and breadth of the CD8+ T cell response was stratified for the 
IFNL3 genotype. As can be seen in figure 4.4, no significant differences in the CD8+ 
T cell response depending on the IFNL3 genotype could be detected in the different 
subgroups. There was also no difference in the CD8+ T cell response depending on 
the IFNL3 genotype in the total cohort (C/C vs. non C/C genotype; data not shown), 
suggesting that the protective effect mediated by the IFNL3 C/C genotype is 
independent of the CD8+ T cell response. 
 
 
Figure 4.4: Magnitude and strength of the CD8+ T cell response according to the IFNL3 
genotype 
The CD8+ T cell response in different subgroups according to the rs12979860 genotype is shown.       
A The relative frequency of IFN-γ+CD8+ T cells after 10 days in vitro expansion for each tested peptide 
is shown. B The percentage of reactive peptides of all tested HLA-matched peptides for each 
individual is shown. Horizontal lines indicate the mean. p-values were calculated using the Kruskal-
Wallis test. 
 
We also divided the two chronic groups and the patients with spontaneously resolved 
HCV infection into HLA-B*27 positive and negative patients. As can be seen in figure 
4.5 the magnitude and breadth of the CD8+ T cell response was slightly elevated in 
0
20
40
60
80
GT1 GT3 RNA neg
   C/C
   non C/C
%
 re
co
gn
is
ed
 p
ep
tid
es
0
1
2
20
40
60
GT1 GT3 RNA neg 
%
 IF
N
-!
+  o
f C
D
8+
 T
 c
el
ls
A B 
  
0
1
2
20
40
60
GT1 GT3 RNA neg
%
 IF
N
-!
+  o
f C
D
8+
 T
 c
el
ls
  
0
20
40
60
80
GT1 GT3 RNA neg
HLA-B*27 neg  
HLA-B*27 pos
%
 re
co
gn
is
ed
 p
ep
tid
es
A B 
Results 
 
 50 
HLA-B*27 positive patients in both the chronically GT1 infected and resolved patients 
compared to HLA-B*27 negative patients, but this increase only reached statistically 
significant levels for the magnitude of the response in GT1 infected patients. 
 
 
Figure 4.5: Magnitude and breadth of the CD8+ T cell response according to the 
HLA-B*27 status 
The CD8+ T cell response in different subgroups according to the HLA-B*27 status is shown. A The 
relative frequency of IFN-γ+CD8+ T cells after 10 days in vitro expansion for each tested peptide is 
shown. B The percentage of reactive peptides of all tested HLA-matched peptides for each individual 
is shown. Horizontal lines indicate the mean. p-values were calculated using the Kruskal-Wallis test  
(*: p<0.05). 
 
For GT3 infected patients the opposite effect could be observed: There was a slight 
decrease in both the breadth and the magnitude of the overall CD8+ T cell response, 
but the difference was not statistically significant.  
Overall, our data for the strength of the CD8+ T cell response is probably not 
conclusive, as too few chronically infected patients were included in this study (2 per 
group) and the majority of tested peptides were skewed towards a GT1 background. 
In addition, only 4 HLA-B*27 epitopes were tested, one of which was restricted by the 
HLA-B*27:02 subtype known to be less common in the general German population 
than the HLA-B*27:05 subtype. 
We therefore wanted to see whether we could identify novel HLA-B*27-restricted 
epitopes in GT3 that might mediate the protective effect of the HLA-B*27 genotype. 
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4.3 Identification of new HLA-B*27-restricted epitopes in GT3a 
In order to identify novel HLA-B*27-restricted epitopes in GT1a, GT1b and GT3a, the 
consensus sequences of all three genotypes were entered into the MHC-I Binding 
Prediction Tool. The 9mers with the highest prediction scores for binding to HLA-
B*27:05, which is the most common HLA-B*27 allele with a frequency of 3.4% in the 
general German population, were synthesized (see table 2.6) and further analysed. 
Additionally, the known HLA-B*27-restricted epitopes p7780 GRWVPGAAY (GT1a), 
NS31492 GRGKPGIYRF (GT1a), GRGRLGTYRY (GT3a) and its GT1b variant 
GRGRRGIYRF (GT1b), NS5B2841 ARMILMTHF (GT1a/1b) and its GT3a variant 
NS5B2841 VRMVMMTHF (GT3a) and NS5B2936 GRAAICGKY (GT1a) were included 
in all further experiments (Giugliano et al., 2009; Neumann-Haefelin et al., 2006). The 
known epitope NS5B2820 ARHTPVNSW (GT1a/1b/3a) was excluded because is it 
known to bind to HLA-B*27:02 instead of HLA-B*27:05 (Nitschke et al., 2014). HLA-
B*27:02 is rare in the general German population. 
 
4.3.1 Identification of two novel vigorously targeted HLA-B*27-restricted 
epitopes against GT3a  
As a first step, the known and predicted HLA-B*27-restricted peptides were tested in 
an in vitro assay to determine whether CD8+ T cell responses against these epitopes 
could be detected in HLA-B*27-positive PWID. For this purpose PBMCs from 13 
PWID were expanded for 10 days in the presence of these peptides, before the IFN-γ 
production by CD8+ T cells was detected via ICS (figure 4.6). 
As shown in figure 4.6A (marked with blue rectangles), IFN-γ-producing CD8+ T cells 
against three novel HLA-B*27-restricted epitopes in GT3a could be detected in 
different PWID. One of the tested PWID displayed a response against the NS5A2094 
epitope, while two PWID showed a CD8+ T cell response against the NS2840 epitope. 
A response against the NS2942 epitope could be detected in 5 PWID, while 3 PWID 
had a detectable response against the known immunodominant GT1 NS5B2841 
epitope. 
The magnitude of the response per epitope was highest for the known 
immunodominant NS5B2841 epitope (mean: 4.82%), followed by the two new GT3a 
epitopes NS840 and NS2942 (means 2.94% and 2.67%, respectively; figure 4.6B). 
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Figure 4.6: CD8+ T cell response against HLA-B*27-restricted epitopes 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of 
predicted and already known HLA-B*27-restricted peptides was examined in 13 HLA-B*27 positive, 
HCV seropositive PWID via ICS and flow cytometric analysis. A Recognition frequencies are shown 
for each tested peptide. B Magnitude of the CD8+ T cell response is shown for each peptide. Each 
circle represents the CD8+ T cell response of one patient. A line indicates the mean. The known 
immunodominant GT1 epitope is marked with a red rectangle, three novel GT3 epitopes are marked 
with blue rectangles. 
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In addition, CD8+ T cell responses could also be detected against the other known 
epitopes p7780 (GT1a), NS31492 (GT1a), NS31492 (GT3a), NS5B2841 (GT3a) and 
NS5B2936 (GT1a) in one or two patients each. A weak response against the 
previously unknown GT1b epitope NS5B2985 was also detected in one patient. 
Overall, the two new GT3a-specific epitopes located in NS2 seemed to be 
comparable to the known GT1-specific NS5B2841 epitope in both the number as well 
as the magnitude of the responses and were therefore analysed further. 
 
4.3.2 Peptide binding to HLA-B*27:05 is high for epitopes that elicit a CD8+ T 
cell response 
As a second step the relative peptide binding of the predicted and known HLA-B*27 
epitopes to HLA-B*27:05 was tested in UV-induced peptide-exchange reactions 
using a high affinity-binding peptide as a control to be able to compare experimental 
results with those obtained by in silico prediction (figure 4.7). 
 
 
Figure 4.7: Peptide binding to HLA-B*27:05 
Binding of peptides containing predicted HLA-B*27:05 epitopes was tested using UV-induced peptide-
exchange reactions. The experiment was performed twice and the bars indicate the mean of the 
percentage of binding relative to a high affinity control (Toebes et al., 2006). *: sequence identical 
between GT1a and GT1b, +: sequence identical between GT1a, GT1b and GT3a, #: sequence 
identical between GT1a and GT3a, §: sequence identical between GT1b and GT3a. 
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NS5B2884 (GT1a/1b) and NS5B2920 (GT3a) (figure 4.7). Nearly all epitopes that had a 
detectable response during the ICS screen (marked in orange in figure 4.7) had 
affinities above 70% of the positive control. This was not unexpected as a high 
binding affinity to the MHC molecule is a necessary but not sufficient criterion for an 
epitope that elicits a CD8+ T cell response. The only exceptions were the GT1b 
epitope NS5B2985, which had a mean binding affinity of 67.6% and was thereby only 
slightly below the 70% cut-off, and the GT1a p7780 epitope, which had a mean 
binding affinity of 42.2%. 
Surprisingly, more than 50% (28 of 54) of the tested peptides had a binding affinity 
below 50% of the positive control even though they were indicated as strong binders 
during the initial prediction step. Interestingly, the GT3a epitopes NS2840 and the 
NS2942, which were the most promising candidates for novel immunodominant GT3a 
epitopes in the ICS screen, also had the highest binding affinities of the GT3a 
epitopes that elicited a CD8+ T cell response. 
 
4.3.3 Ex vivo frequency of HLA-B*27-restricted CD8+ T cells is comparable for 
the GT3a-specific NS2940 and the GT1-specific NS5B2841 epitopes 
As our initial analysis of the CD8+ T cell response against HLA-B*27 restricted 
epitopes consisted of an ICS screen and was therefore biased towards HCV-specific 
cells that could be expanded and were functional, i.e. produced IFN-γ, we wanted to 
examine the CD8+ T cell responses directed against the two GT3a epitopes in NS2 
directly ex vivo. As a comparison the immunodominant GT1 epitope NS5B2841 was 
also included in this analysis. 
For this purpose we used MHC class I dextramers, which consist of a dextran 
polymer backbone coupled to several MHC-peptide complexes and fluorochromes. 
The dextramers can thus bind to several TCRs on the surface of a CD8+ T cell and 
allow direct staining and sensitive detection of HCV-specific CD8+ T cells including 
functionally impaired and exhausted CD8+ T cells. 
25 HLA-B*27 positive PWID were stained with MHC class I dextramers and the 
frequency of NS5B2841-, NS2840- and the NS2942-specific CD8+ T cells was 
determined via flow cytometry. In 18 PWID CD8+ T cells directed against the 
previously described NS5B2841 epitope were detectable and in 13 PWID CD8+ T cells 
directed against the NS2942 epitope were detectable (figure 4.8A). CD8+ T cell 
directed against the NS2840 epitope were detectable in fewer PWID (n=6). The mean 
Results 
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magnitude of the dextramer response was in a similar range for the NS5B2841 epitope 
(0.130%) and the NS2942 epitope (0.116%), while the response against the NS2840 
epitope was again lower (0.054%) (figure 4.8B). 
 
 
Figure 4.8: Ex vivo CD8+ T cell response against HLA-B*27 restricted epitopes  
The relative frequency of HCV-specific CD8+ T cells was determined via MHC class I dextramer 
staining directly after thawing. A Recognition frequencies are shown for each tested dextramer. 
Dextramer responses were counted as positive if they constituted at least 0.004% of the total CD8+ T 
cell population and a distinct population could be identified. B Magnitude of the CD8+ T cell response 
is shown for each epitope. Each circle represents the CD8+ T cell response of one patient. A line 
indicates the mean.  
 
4.3.4 Memory phenotype of HLA-B*27 restricted CD8+ T cells 
To further characterise the CD8+ T cell response directed against the two new NS2 
epitopes as well as the NS5B2841 epitope, we wanted to take a closer look at the 
memory phenotype of the CD8+ T cell responses. The IL-7 receptor α-chain, also 
known as CD127, is a key molecule for the maintenance of memory T cell 
populations and has been previously associated with superior functionality against 
HCV (Seigel et al., 2013). Moreover, upregulation of CD127 on HCV-specific CD8+ T 
cells was observed after either viral clearance or upon viral sequence variation 
(Kasprowicz et al., 2010). We therefore wanted to utilise this marker and correlate it 
to the proliferation potential of the HCV-specific CD8+ T cells. 
To achieve this, specific cells were stained with MHC class I dextramers directly after 
thawing (ex vivo) and after 7 days of peptide-specific expansion (day 7) and the 
CD127 expression of CD8+dextramer+ cells was determined ex vivo (figure 4.9A). 
The fold increase of CD8+dextramer+ cells between the two time points was then 
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calculated and correlated to either high or low CD127 expression on these cells 
(figure 4.9B).  
 
 
Figure 4.9: Memory phenotype of HLA-B*27 restricted HCV-specific CD8+ T cells 
A Frequencies of NS5B2841-, NS2840- and the NS2942-specific CD8+ T cells were determined directly 
after thawing and after 7 days of peptide-specific expansion via MHC class I dextramer staining and 
subsequent flow cytometric analysis. CD127 expression on HCV-specific CD8+ T cells was 
determined ex vivo. Exemplary FACS plots are shown for two PWID with responses against the 
NS5B2841 and the NS2942 epitope. B Fold increase of CD8+dextramer+ T cells between day 0 and day 
7 was calculated and stratified for CD127 expression ex vivo. Cells were classified as CD127low, if the 
CD127 expression was below 60%, otherwise cells were classified as CD127high. The p-value was 
calculated using Mann Whitney test. 
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The fold increase of CD8+dextramer+ cells between day 0 and day 7 with low CD127 
expression (under 60%) was significantly lower compared to that of CD8+dextramer+ 
cells with high CD127 expression. This is in line with previous data that indicates that 
HCV-specific cells with low CD127 expression have a lower proliferative potential 
than those with high CD127 expression (Bengsch et al., 2010). In this study by 
Bengsch et al. high CD127 expression on HCV-specific cells of chronic patients was 
also linked to viral escape in the respective epitope. The two lowest CD127 
expression values were found in PWID396 and PWID470 (figure 4.9A), who were 
both chronically HCV infected. Consequently, we wanted to examine the viral 
sequence in these epitopes in more detail.  
 
4.3.5 Low CD127 expression is present on HCV-specific cells that target 
epitopes with intact viral sequences in chronic PWID 
First, we examined the viral sequence in the NS5B2841 epitope in GT1 infected 
patients (table 4.4). The majority of patients had two or more sequence 
polymorphisms, while two patients had none or only one substitution. The pattern of 
sequence polymorphisms was similar to that observed in other studies of this epitope 
(Dazert et al., 2009; Neumann-Haefelin et al., 2006, 2010). In PWID396, who had 
low CD127 expression on CD8+ T cells targeting the NS5B2841 epitope (figure 4.9A), 
the epitope had an alanine to valine substitution in the first position of the epitope. 
Even though the viral sequence was not completely intact, it has been shown that 
this viral polymorphism is still completely cross-reactive with T cells targeting the 
original epitope. This substitution on its own does therefore not confer viral escape 
(Dazert et al., 2009). The other patient without substitutions in the NS5B2841 epitope 
was PWID545, for whom no responses against this epitope could be detected. 
 
Table 4.4: Autologous viral sequence of the NS5B2841 epitope in GT1 infected patients 
ID GT NS5B2841 
consensus 1a/1b A R M I L M T H F 
PWID093 1a . . . V M . . . . 
PWID159 1a V . . V . L . . . 
PWID221 1a V . . V . . . . . 
PWID309 1a V . . . . L . . . 
PWID425 1a V . . . . L . . . 
PWID545 1a . . . . . . . . . 
PWID396 1b V . . . . . . . . 
 
Next, we also sequenced the two NS2 epitopes in GT3a infected patients (table 4.5).  
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Table 4.5: Autologous viral sequence of the NS2840 and NS2942 epitopes in GT3a 
infected patients 
HLA-B*27 ID GT NS2840 p-value+ NS2942 p-value 
  consensus 3a G R L I W W N Q Y  G R W F N T Y L Y  
pos PWID319 3a S . . . . . . . . 0.2047 . . . . . . . . . 0.0016 
 PWID390   S . . . . . . . .   . . . C . . . . .  
 PWID429  . . . V . . . R .  A . . . . . . . .  
 PWID470   S . I . . . . . .   . . . . . . . . .  
 PWID524   A . . M . . . . .   . K . . . . . . .  
 FB001   . . . M . . . . .   . . . . . . . . .  
 FB002   S . . . . . . . .   . . . C . . . . .  
 FB003   . . . M . . . . .   . . Y . . . . . .  
 FB004   . . . M . . . . .   . . . . . . . . .  
 FB007   . . I M . . . . .   . K . . . . . . .  
 FB008   . . . M . . . . .   . . . . . . . . .  
 FB010   . . . . . . . . .   . . . . . . . . .  
 FB011   . . . . . . . . .   . . . . . . . . .  
 FB012   . . . M . . . . .   . . . C . . . . .  
 FB013   S . . M . . . . .   . . . C . . . . .  
  FB014   . . . M . . . . .   . . . . . . . . .   
neg PWID004 3a S . . . . . . . .   . . . . . . . . .  
 PWID022   . . . . . . . . .   . . . . . . . . .  
 PWID032   S . . . . . . . .   . . . . . . . . .  
 PWID036   . . . . . . . . .   . . . . . . . . .  
 PWID044   . . . M . . . . .   . . . . . . . . .  
 PWID063   . . . M . . . . .   . . . . . . . . .  
 PWID064   . . . . . . . . .   . . . . . . . . .  
 PWID070   . . . . . . . . .   . . . . . . . . .  
 PWID076   . . . M . . . . .   . . . . . . . . .  
 PWID079   . . . M . . . . .   . . . . . . . . .  
 PWID092   . . . . . . . . .   . . L . . . . . .  
 PWID096   . . . M . . . . .   . . . . . . . . .  
 PWID112   S . I . . . . . .   . . . . . . . . .  
 PWID113   S . I . . . . . .   . . . . . . . . .  
 PWID114   . . . . . . . . .   . . . . . . . . .  
 PWID120   S . . M . . . . .   . . . . . . . . .  
 PWID122   C . . . . . . . .   . . . . . . . . .  
 PWID127   . . . . . . . . .   . . . . . . . . .  
 PWID132   . . . M . . . . .   . . . . . . . . .  
 PWID144   . . . M . . . . .   . . . . . . . . .  
 PWID150   . . . . . . . . .   . . . . . . . . .  
 PWID163   . . . M . . . . .   . . . . . . . . .  
 PWID174   . . . M . . . . .   . . . C . . . . .  
 PWID176   . . . . . . . . .   . . . . . . . . .  
 PWID182   . . . M . . . . .   . . F . . . . . .  
 PWID195   . . . M . . . . .   . . . . . . . . .  
 PWID207   . . . M . . . . .   . . . . . . . . .  
 PWID217   S . . . . . . . .   . . . . . . . . .  
 PWID240   . . . . . . . . .   . . . . . . . . .  
 PWID245   S . . M . . . . .   . . . . . . . . .  
 PWID249   . . . . . . . . .   . . . . . . . . .  
 PWID274   . . . M . . . . .   . . . . . . . . .  
 PWID281   . . . M . . . . .   . . . . . . . . .  
 PWID285   . . . M . . . . .   . . . . . . . . .  
 PWID292   . . . . . . . . .   . . . . . . . . .  
 PWID295   S . . . . . . . .   . . . . . . . . .  
 PWID300   . . . . . . . . .   . . . . . . . . .  
 PWID303   . . . M . . . . .   . . . . . . . . .  
 PWID316   . . . . . . . . .   . . . . . . . . .  
 PWID331   S . . . . . . . .   . . . C . . . . .  
 PWID335   S . . . . . . . .   . . . . . . . . .  
 PWID336   S . . M . . . . .   . . . . . . . . .  
 PWID340   . . . M . . . . .   . . . . . . . . .  
 PWID346   . . . . . . . . .   . . . . . . . . .  
 PWID347   S . . . . . . . .   . . . . . . . . .  
 PWID350   . . . . . . . . .   . . . . . . . . .  
 PWID352   . . . M . . . . .   . . . L . . . . .  
 PWID359   . . . . . . . . .   . . . . . . . . .  
 PWID382   . . . M . . . . .   . . . . . . . . .  
 PWID387   . . . . . . . . .   . . . . . . . . .  
 PWID449   . . . M . . . . .   . . . . . . . . .  
 PWID463   . . . M . . . . .   . . . . . . . . .  
 PWID467   . . . M . . . . .   . . . . . . . . .  
 PWID468   . . . M . . . . .   . . . C . . . . .  
 PWID501   . . . M . . . . .   . . . . . . . . .  
  PWID503   . . . M . . . . .   . . . . . . . . .   
Positions with sequence polymorphisms are shaded in gray; +: p-values for the association between the frequency of sequence 
polymorphisms and the presence of HLA-B*27 were calculated using Fisher’s exact test. 
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The second chronically infected patient with low CD127 expression on its HCV-
specific CD8+ T cells (PWID470, NS2942-specific CD8+ T cells) displayed no 
mutations in this epitope. As in the study by Bengsch et al. HCV-specific CD8+ T cells 
with very low CD127 expression had low proliferative capacity probably caused by 
ongoing antigen triggering due to lack of escape mutations in the corresponding 
epitopes. The second patients without substitutions in the NS2942 epitope (PWID319) 
again had no detectable CD8+ T cell response against this epitope. 
 
4.3.6 Escape mutations in the NS2942 epitope 
As only very few sequences were available in these two regions for GT3a in the Los 
Alamos HCV sequence database, we sequenced the autologous virus from 56 
chronically 3a infected HLA-B*27-negative PWID (table 4.5). For the HLA-B*27-
positive patients we included another 11 HLA-B*27-positive patients chronically 
infected with GT3a from a previously published cohort of the University of Freiburg 
(Neumann-Haefelin et al., 2010), because only very few PWID with GT3a infection 
were present in our cohort. Overall, the sequence variability was greater in the 
NS2840 epitope compared to the NS2942 epitope and here position 1 and 4 showed 
the greatest variability (figure 4.10A). Importantly, in position 4 isoleucine and 
methionine were both equally likely and no difference in the frequency could be found 
between HLA-B*27 positive and HLA-B*27 negative PWID indicating that this residue 
was not under selection pressure by HLA-B*27. Polymorphisms at different positions 
of the epitope were not more likely to occur in HLA-B*27 positive patients compared 
to HLA-B*27 negative patients (p=0.2047, table 4.5). Collectively, there was no 
evidence for HLA-B*27 mediated escape in the NS2840 epitope. 
The NS2942 epitope was more conserved with 89.3% of sequences corresponding to 
the prototype. The only positions showing any variability were positions 2, 3 and 4 of 
the epitope (figure 4.10B). When the frequency of sequence polymorphisms in the 
whole epitope were compared between HLA-B*27 positive and negative patients, 
polymorphisms in the NS2942 epitope were significantly more frequent in HLA-B*27 
positive patients (p=0.0016, Fisher’s exact test) strongly suggesting that the epitope 
is under selection pressure in the presence of HLA-B*27.  
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Figure 4.10: Sequence variability of the NS2840 and NS2942 epitopes in HLA-B*27 
negative PWID 
Mean pairwise sequence identity per individual residue was determined using Geneious. 
 
To analyse the relevance of these substitutions on the CD8+ T cell response, we 
performed cross-reactivity studies via ICS. First, we examined the polymorphism 
between isoleucine and methionine at position 4 of the NS2840 epitope in more detail. 
As can be seen in figure 4.11A, CD8+ T cell responses against the GRLIWWNQY 
variant (GT3a, dark blue bars) also recognised the GRLMWWNQY variant (GT3a V1, 
light blue bars). In both cases CD8+ T cells could also be expanded in the presence 
of the GT3a V1 variant, but the frequency of expanded cells differed considerably 
between patients from barely detectable in PWID488 to higher frequencies than the 
prototype GT3a variant in PWID519. The I4M polymorphism seems to have an 
influence on the CD8+ T cell response, but there is little evidence for immune escape 
based on the cross-reactivity profile. 
Next, we wanted to examine the autologous viral sequences of the HLA-B*27 
positive chronically GT3a infected PWID in more detail. As a first step, we tried to 
expand CD8+ T cell responses with peptides corresponding to the autologous viral 
sequence of the NS2840 and NS2942 epitope in patients harbouring the respective 
sequence. After 10 days of expansion the cells were restimulated with the same 
peptides, but no response could be detected in any of the patients (data not shown). 
This result was not surprising, as no response could be detected after expansion and 
restimulation with the prototype sequences, either (data not shown). 
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Figure 4.11: CD8+ T cell response against the prototype HLA-B*27-restricted NS2840 
and NS2942 epitopes and the corresponding autologous viral sequences  
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*27-restricted peptides NS2840 (A) or NS2942 (B) was examined in HLA-B*27 positive, PWID 
who had a measurable response against either of these epitopes during the initial ICS screen. Cross-
reactivity of CD8+ T cells was evaluated by ICS for IFN-γ after restimulation with either the GT3a or 
autologous viral sequence peptide (GT3a V1-4). Each bar represents the CD8+ T cell response to one 
peptide.  
 
As a second step, expansion with the autologous viral sequence peptides as well as 
the prototype sequence was performed in PWID that displayed a response against 
the prototype sequence (figure 4.11).  
For the NS2840 epitope, the CD8+ T cell line expanded in the presence of the 
prototype sequence GRLIWWNQY could also elicit a response when it was 
restimulated with HLA-B*27-associated variant epitope sequences, although the 
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magnitude of the response differed (figure 4.11A). In both tested patients the 
magnitude of the CD8+ T cell response was nearly identical between the prototype 
sequence and the SRLIWWNQY variant (GT3a V2). The magnitude of the response 
was reduced by nearly 50% for the ARLMWWNQY variant (GT3a V4), while it was 
even lower for the SRIIWWNQY variant (GT3a V3). The ARLMWWNQY variant 
could also be used to expand CD8+ T cells in both patients, while for the other two 
variants this was only possible for PWID519. In all cases the CD8+ T cells expanded 
in the presence of the autologous viral sequences were fully cross-reactive with the 
prototype sequence. Collectively, these data suggest that the variant V3 may act as 
an escape variant, while the other variants are not associated with immune escape. 
Taken together, most of the sequence variations in the NS2840 epitope are 
immunogenic and unlikely to be the product of immune selection pressure.  
In contrast, CD8+ T cells expanded with the NS2942 prototype sequence displayed no 
or minimal cross-reactivity with the GKWFNTYLY variant (GT3a V1) or the 
GRWCNTYLY variant (GT3a V2) in the four tested patients (figure 4.11B). Only 
PWID488 showed some cross-reactivity between the prototype sequence and the 
GKWFNTYLY variant (GT3a V1). This was quite surprising, as the substitution for 
this variant is at position 2 of the epitope and therefore in one of the anchor positions 
for MHC binding. Mutations in this position usually result in impaired binding to the 
MHC molecule and would therefore result in an accelerated off-rate of the variant 
peptide from the MHC molecule. To exclude that this result was an artefact of the 
continuous presence of the peptide, we loaded PBMC from another HLA-B*27 
positive donor with either the prototype peptide or the autologous viral sequence 
peptide and washed them extensively before using these cells for restimulation 
(figure 4.12). This way only peptide properly bound to the MHC molecule of the donor 
PBMCs was available for restimulation while excess peptide was washed away. 
PBMCs pulsed with the prototype peptide elicited CD8+ T cell responses of roughly 
the same magnitude as those generated by direct peptide stimulation. In contrast, the 
CD8+ T cell responses caused by PBMCs pulsed with the variant peptide were nearly 
ten fold reduced compared to those elicited by direct peptide stimulation. In this case 
the stability of the MHC-peptide complex may not have been sufficient causing the 
variant peptide to be removed during the washing steps. Responses against the 
either the prototype or the variant sequences were again barely detectable in the 
CD8+ T cell line expanded with the variant peptide. 
Results 
 
 63 
 
Figure 4.12: CD8+ T cell response against the NS2942 epitopes with direct peptide 
stimulation or peptide loaded cells 
The relative frequency of CD8+IFN-γ+ T cells after 14 days of in vitro expansion in the presence of the 
HLA-B*27-restricted peptide NS2942 was examined in the HLA-B*27 positive PWID488. Cross-
reactivity of CD8+ T cells was evaluated by ICS for IFN-γ after restimulation with either direct peptide 
stimulation with the GT3a or autologous viral sequence peptide (GT3a V1) or HLA-B*27 positive 
PBMC pulsed with either peptide.  
 
In summary, there is no evidence for HLA-B*27 mediated escape mutations in the 
NS2840 epitope, as the mutations that occur in this epitope are not more frequent in 
HLA-B*27 positive patients and do not abrogate recognition by CD8+ T cells 
recognising the prototype sequence. In contrast, true escape mutations seem to be 
selected in the NS2942 epitope that act either through abrogation of TCR recognition 
(GRWCNTYLY variant) or through a decrease in binding to the MHC molecule 
(GKWFNTYLY variant). 
 
4.3.7 Both NS2 epitopes are only immunogenic in GT3a 
Next, we wanted to determine, whether these two epitopes might also be 
immunogenic in GT1a and GT1b or whether cross-reactivity between the different 
genotypes might occur. As a first step, we looked at the sequences available in the 
Los Alamos HCV sequence database (table 4.6). Although there was extensive 
sequence variation in both epitope regions in genotype 1a and 1b, the genotype 3a 
prototype epitope sequences were absent from all GT1 sequences studied. In fact, 
all GT1a sequences harboured multiple substitutions (≥ 4 substitutions) and all GT1b 
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sequences harboured ≥2 substitutions compared to the GT3a prototype sequences 
in both epitopes.  
 
Table 4.6: Alignment of sequences covering the NS2840 and NS2942 epitopes from the 
HCV database 
source GT NS2840  % NS2942 % 
tested peptide 3a GRLIWWNQY  GRWFNTYLY  
HCV sequence database 1a SWCL..L.. 71.10 .ALTG..V. 75.52 
(n=301, n=143)  SWCM..L.. 4.98 .ALTG..I. 15.38 
  SWC...L.. 3.32 .ALAG..V. 2.80 
  SWCF..L.. 3.32 .ALTG..VF 2.10 
  SWCL..L.X 2.33 other 4.20 
  CWCL..L.. 1.66   
  SWCV..L.. 1.33   
  .WCL..L.. 1.33   
  SWCL..I.. 1.33   
  SWCX..L.. 1.00   
  other* 16.34   
HCV sequence database 1b A.....L.. 54.80 AALTG..V. 85.65 
(n=250, n=230)  AK....L.. 23.60 .ALTG..V. 3.91 
  A.....S.. 4.00 AALTG..I. 2.61 
  A..M..L.. 2.40 .ALTG..I. 2.17 
  AK....S.. 2.00 other 4.33 
  T.....L.. 1.60   
  A.I...L.. 1.60   
  A..L..L.. 1.20   
  A.F...L.. 1.20   
  other 7.6   
HCV sequence database 3a ......... 28.57 ......... 75.00 
(n=7, n=4)  ...M..... 14.29 ADGS..... 25.00 
  A........ 14.29   
  S..M..... 14.29   
  A..M..... 14.29   
  ...M..X.. 14.29   
*: all sequences with a frequency below 1% were summarised as other, at least 2 amino acid 
differences compared to the GT3a consensus sequence were present  
 
Even though the GT3a prototype sequences differed greatly from both the GT1a and 
GT1b consensus sequences, we wanted to determine whether the GT1a and GT1b 
sequences might still elicit CD8+ T cell responses. For this purpose these sequences 
were also tested in an ICS screen with PBMCs from HLA-B*27-positive PWID, who 
had either resolved infection or were chronically GT1 infected (figure 4.13A).  
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Figure 4.13: CD8+ T cell responses against GT1a, GT1b and GT3a variants of the 
NS2840 and NS2942 epitopes 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*27-restricted peptides NS2840 and NS2942 was examined in HLA-B*27 positive PWID via ICS 
and flow cytometric analysis. A Exemplary FACS plots are shown for the NS2942 epitope in PWID553. 
Cross-reactivity of CD8+ T cells was evaluated by ICS for IFN-γ after restimulation with either the 
GT1a, GT1b or GT3 peptide of the NS2840 (B) and NS2942 (C) epitope.  
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After analysing the CD8+ T cell immune response in 3 PWID, no IFN-γ response was 
detected after expansion and restimulation with either the GT1a or GT1b peptides, 
while responses targeting the corresponding GT3a sequence of the NS2840 epitope 
were still readily detectable (figure 4.13B). In one patient (PWID029) there was 
minimal cross-reactivity between the GT3a variant and the GT1b variant. For the 
NS2942 epitope the CD8+ T cells expanded with the GT3a sequence did not show any 
cross-reactivity with any of the GT1 sequences. No GT1-specific responses could be 
detected in any of the four tested patients. Taken together, these data seem to 
indicate that even though both the NS2840 and the NS2942 sequences constitute 
epitopes in GT3a, the corresponding sequences in GT1a and GT1b do not seem to 
be immunogenic. 
Overall, we were able to show that HLA-B*27 is associated with spontaneous 
clearance of both GT1 and GT3 HCV infection in the PWID cohort. The protective 
effect of HLA-B*27 during GT1 infection has been previously linked to the 
immunodominant epitope NS5B2841 (Neumann-Haefelin et al., 2006, 2010), which 
was also the most frequently recognised HLA-B*27 restricted epitope in our cohort. In 
addition, we could identify two novel HLA-B*27 restricted epitopes in GT3 including 
one immunodominant epitope associated with mutational escape in HLA-B*27-
positive individuals that might explain the protective effect of this HLA molecule 
during GT3 infection. Importantly, the GT3a-specific NS2942 epitope was recognised 
nearly as often and with a similar magnitude as the GT1-specific NS5B2841 epitope. 
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4.4 T cell responses targeting different variants of the same epitope 
Not only genetic host factors, but also genotype-specific differences in the elicited 
CD8+ T cell response can play an important role in determining the outcome of HCV 
infection. Our group has previously shown that patients with CD8+ T cells active 
against both GT1 and GT3 are predominantly found in PWID with resolved infection 
(Giugliano et al., 2009). These included CD8+ T cell responses that were cross-
reactive between the different genotypes as well as genotype-specific responses, in 
which case two distinct T cell responses targeting the different genotypes could be 
detected within one patient. Here, we aimed to determine the frequency of co-
existing HCV genotype-specific CD8+ T cell populations in highly exposed PWID. We 
were especially interested in CD8+ T cell responses restricted by HLA molecules that 
have been shown to be protective during viral infections. These include HLA-B*13 
and HLA-B*15, which have been associated with decreased viral loads during human 
immunodeficiency virus (HIV) infection with clade C (Honeyborne et al., 2007; Tang 
et al., 2002) and clade B (Frahm et al., 2006), respectively, as well as HLA-B*27 and 
HLA-B*57, which have been associated with slower disease progression during HIV 
infection (Goulder and Watkins, 2008; Kaslow et al., 1996; McNeil et al., 1996; 
Trachtenberg et al., 2003) and spontaneous viral clearance during HCV infection 
(Kim et al., 2011; Kuniholm et al., 2010; McKiernan et al., 2004; Thio et al., 2002). 
Only immunodominant epitopes, in which binding to the MHC molecule was not 
potentially impaired due to substitutions in MHC binding anchor positions, were 
included in this study. 
 
4.4.1 HLA-B*27 restricted epitopes NS31492 and NS5B2841 
As a first example we wanted to examine the HLA-B*27 restricted epitope NS31492, 
because CD8+ T cell responses against both the GT1a and the GT3a variants of this 
epitope have been described (Giugliano et al., 2009; Neumann-Haefelin et al., 2006), 
but cross-reactivity and simultaneous occurrence in one patient had not been 
previously explored. We tested the cross-reactivity of all three variants (GT1a, GT1b, 
GT3a) in 25 HLA-B*27 positive PWID via ICS staining and flow cytometric analysis. 
As can be seen in figure 4.14, five PWID displayed a response against at least one 
variant of this epitope. In two patients a response against both the GT1a and the 
GT3a sequence was detectable, but no cross-reactivity occurred between these two 
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variants. Additionally, two patients only had a response against the GT3a sequence, 
while one patient only showed a response against the GT1a sequence. No 
responses against the GT1b variant were detected. 
 
Figure 4.14: CD8+ T cell response against the HLA-B*27-restricted epitope NS31492 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*27-restricted peptides NS31492 was examined in 25 HLA-B*27 positive, HCV seropositive PWID 
via ICS and flow cytometric analysis. Cross-reactivity of CD8+ T cells was evaluated by ICS for IFN-γ 
after restimulation with either the GT1a, GT1b or GT3a peptide. Each bar represents the CD8+ T cell 
response to one peptide. 
 
As a second example we wanted to examine the HLA-B*27 restricted 
immunodominant epitope NS5B2841. Even though a similar study did not find any 
responses against the GT3a variant of this epitope (Neumann-Haefelin et al., 2010), 
we found two relatively weak responses against this epitope during our initial screen 
in GT3a infected PWID (see figure 4.6). As the study by Neumann-Haefelin et al. did 
not include patients who had resolved a GT3a infection, we wanted to have a closer 
look at this epitope in our PWID cohort, in which patients are regularly exposed to 
both genotypes. 
CD8+ T cell responses against the GT1 variant of the epitope were detected in 14 
PWID, while 10 PWID showed some sort of response against the GT3 variant of this 
epitope (figure 4.15). In most cases, the GT3 response was a lot weaker than the 
PW
ID
09
3
PW
ID
15
9
PW
ID
22
1
PW
ID
30
9
PW
ID
42
5
PW
ID
54
5
PW
ID
39
6
PW
ID
31
9
PW
ID
39
0
PW
ID
42
9
PW
ID
47
0
PW
ID
52
4
PW
ID
02
9
PW
ID
03
5
PW
ID
21
1
PW
ID
23
9
PW
ID
27
9
PW
ID
28
8
PW
ID
29
4
PW
ID
36
9
PW
ID
43
4
PW
ID
46
9
PW
ID
48
8
PW
ID
51
9
PW
ID
55
3
0
10
20
30
40
stim GT1a restim GT1a
stim GT1a restim GT1b
stim GT1a restim GT3a
stim GT1b restim GT1a
stim GT1b restim GT1b
stim GT1b restim GT3a
stim GT3a restim GT1a
stim GT3a restim GT1b
stim GT3a restim GT3a
GT1a GT1b GT3a RNA neg
GT1a: GRGKPGIYRF
GT1b: GRGRRGIYRF
GT3a: GRGRLGTYRY
%
 IF
N
-!
+  o
f C
D
8+
 T
 c
el
ls
Results 
 
 69 
GT1 response and was probably caused by cross-reactivity of the GT1 response. In 
contrast to this, in four patients a response of nearly equal or even greater magnitude 
was detected against the GT3 sequence. Interestingly, these patients were either 
chronically GT3a infected (PWID470) or showed evidence for a previously resolved 
GT3a infection in the form of CD8+ T cell responses against other GT3a-specific 
responses (either NS31492 (see figure 4.14), NS2840 or NS2942 (data not shown)). 
 
 
Figure 4.15: CD8+ T cell response against the HLA-B*27-restricted epitope NS5B2841 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*27-restricted peptides NS5B2841 was examined in 25 HLA-B*27 positive, HCV seropositive 
PWID via ICS and flow cytometric analysis. Cross-reactivity of CD8+ T cells was evaluated by ICS for 
IFN-γ after restimulation with either the GT1 or GT3 peptide. Each bar represents the CD8+ T cell 
response to one peptide. 
 
4.4.2 HLA-B*13 restricted epitope NS31627 
As a next example the previously described CD8+ T cell immune response against 
the immunodominant HLA-B*13-restricted NS31627 was analysed in 18 HLA-B*13 
positive PWID. For this epitope the GT1a and GT1b sequences are identical 
(RLGAVQNEV, labelled GT1) and only the GT3a sequence shows any sequence 
variation (RLGPVQNEI, labelled GT3). 
A response against either one or both genotype-specific peptides could be detected 
in 12 out of 18 patients (figure 4.16). Half of the tested patients displayed two distinct 
T cell population directed against both genotypes, even though the strength of the 
PW
ID
09
3
PW
ID
15
9
PW
ID
22
1
PW
ID
30
9
PW
ID
42
5
PW
ID
54
5
PW
ID
39
6
PW
ID
31
9
PW
ID
39
0
PW
ID
42
9
PW
ID
47
0
PW
ID
52
4
PW
ID
02
9
PW
ID
03
5
PW
ID
21
1
PW
ID
23
9
PW
ID
27
9
PW
ID
28
8
PW
ID
29
4
PW
ID
36
9
PW
ID
43
4
PW
ID
46
9
PW
ID
48
8
PW
ID
51
9
PW
ID
55
3
0
20
40
60
stim GT1 restim GT1
stim GT1 restim GT3
stim GT3 restim GT1
stim GT3 restim GT3
GT1a GT1b GT3a RNA neg
GT1: ARMILMTHF
GT3: VRMMVMTHF
%
 IF
N
-!
+  o
f C
D
8+
 T
 c
el
ls
Results 
 
 70 
two responses differed widely between the patients from barely detectable for one 
genotype to equal in strength for both genotypes. In GT1 infected patients and in 
patients with resolved HCV infection 3 out of 6 patients exhibited CD8+ T cell 
responses against either of the variant epitopes, while at least one of the responses 
could be detected in all GT3 infected patients. 
 
Figure 4.16: CD8+ T cell response against the HLA-B*13-restricted epitope NS31627 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*13-restricted peptides NS31627 was examined in 18 HLA-B*13 positive, HCV seropositive PWID 
via ICS and flow cytometric analysis. Cross-reactivity of CD8+ T cells was evaluated by ICS for IFN-γ 
after restimulation with either the GT1 or GT3 peptide. Each bar represents the CD8+ T cell response 
to one peptide. 
 
Surprisingly, the most responses against both genotypes could also be found in GT3 
infected subjects (5 out of 6), while only 2 out of 6 subjects each had a response 
against both genotypes in the GT1 infected PWID and PWID with resolved infection.  
In the majority of cases these T cells were either not cross-reactive at all or only 
cross-reactive to a very small degree. The only exception to this observation was 
PWID 370, whose PBMCs were fully cross-reactive between both genotypes. 
As a next step we wanted to show that the two genotype-specific responses within 
one subject actually represent two distinct T cell populations that arose from different 
precursor cells. For this purpose all subjects with at least one reponse against one of 
the HLA-B*13 epitope variants were analysed for their TCR Vβ chain usage via flow 
cytometric analysis (figure 4.17A). 
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Figure 4.17: Vβ repertoire of HLA-B*13 NS31627-specific CD8+ T cells 
PWID with positive IFN-γ responses against GT1 or GT3 were further analysed for their TCR Vβ chain 
usage via flow cytometry. A Gating strategy for identification of HCV-specific CD8+ T cells with certain 
Vβ chains. Gating for Vβ pool 1 is shown as an example. B Vβ repertoire of RLGAVQNEV (GT1)-
specific CD8+ T cells. C Vβ repertoire of RLGPVQNEI (GT3)-specific CD8+ T cells. 
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The subjects that had a response against the GT1 epitope mainly displayed Vβ1, 
Vβ2, Vβ11, Vβ12 and Vβ21.3 on their surface (figure 4.17B), whereas subjects with a 
GT3-specific response mainly displayed Vβ7.1, Vβ14, Vβ16 and Vβ22 on their 
surface (figure 4.17C). Taken together these data indicate that the CD8+ T cells 
recognising the two different genotype-specific variants of the HLA-B*13 epitope use 
distinct TCR Vβ repertoires.  
 
4.4.3 HLA-B*15-restricted epitope NS5B2466 
Subsequently, we tested the CD8+ T cell response against the HLA-B*15 restricted 
epitope NS5B2466. For this epitope the viral consensus sequence differs not only 
between GT1 and GT3, but also between the subtypes GT1a and GT1b. Therefore 
all 9 possible combinations were tested for their respective cross-reactivity (figure 
4.18). 
 
 
Figure 4.18: CD8+ T cell response against the HLA-B*15-restricted epitope NS5B2466 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*15-restricted peptides NS5B2466 was examined in 12 HLA-B*15 positive, HCV seropositive 
PWID via ICS and flow cytometric analysis. Cross-reactivity of CD8+ T cells was evaluated by ICS for 
IFN-γ after restimulation with either the GT1a, GT1b or GT3a peptide. Each bar represents the CD8+ T 
cell response to one peptide. 
 
PWID204 PWID223 PWID395 PWID210 PWID214 PWID258 PWID176 PWID229 PWID352 PWID142 PWID213 PWID225
0
20
40
60
stim GT1a restim GT1a
stim GT1a restim GT1b
stim GT1a restim GT3a
stim GT1b restim GT1a
stim GT1b restim GT1a
stim GT1b restim GT3a
stim GT3a restim GT1a
stim GT3a restim GT1b
stim GT3a restim GT3a
GT1a: CQRQKKVTF 
GT1b: SQRQKKVTF
GT3a: SQRQRKVTF
  
%
 IF
N
-!
+  o
f C
D
8+
 T
 c
el
ls
GT1a GT1b GT3a RNA neg
Results 
 
 73 
CD8+ T cell responses could mainly be detected against GT1a and GT1b. The GT1b-
specific response was the predominant one, which could be observed in 8 out of 12 
patients, while a GT1a-specific response was detectable in 6 patients. GT1a-specific 
responses were only observed in conjunction with GT1b-specific responses. In 
addition, these responses were fully cross-reactive between GT1a and GT1b, but the 
GT1b response was usually stronger. The detected GT3a-specific responses were 
relatively weak and were only found in three patients. No cross-reactivity was 
observed between GT1-specific cells and the GT3a epitope and GT3a-specific CD8+ 
T cells from only one patient (PWID225) showed minimal cross-reactivity with both 
GT1 epitopes. 
To further analyse these different genotype- and subtype-specific responses, the 
TCR Vβ chain usage in patients with CD8+ T cell responses against more than one 
genotype variant were determined via flow cytometry (figure 4.19). 
Within one patient the Vβ chains used in GT1a and GT1b-specific cells were always 
identical, even if the usage differed between patients. For example, Vβ3 (figure 
4.19A), Vβ5.1 and Vβ20 (figure 4.19B), V β14 (figure 4.19C) and Vβ17 (figure 4.19D) 
were observed on GT1a- and GT1b-specific cells in different patients. The presence 
of the same Vβ chains on both GT1-specific cells within each patient might be 
another indicator for the cross-reactivity of these cells. 
The Vβ repertoire of all three genotypes could only be compared for PWID225 (figure 
4.19D). For this patient the GT1a- and GT1b-specific CD8+ T cells nearly exclusively 
displayed Vβ17 on their surface. This was only true for about 25% of GT3a-specific 
cells, while Vβ13.2 was present on another 25% of GT3a-specific cells. The 
presence of Vβ17 on CD8+ T cells recognising all three genotypes might explain the 
slight cross-reactivity the GT3-specific cells exhibited towards the GT1 epitopes. 
Overall, subtype-specific GT1 responses were largely cross-reactive and were 
recognised by TCRs using the same Vβ chains, while the GT3 response was not 
cross-reactive with either GT1 response and the corresponding TCR used a different 
Vβ chain. 
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Figure 4.19: Vβ repertoire of HLA-B*15 NS5B2466-specific CD8+ T cells 
PWID with positive IFN-γ responses against two or more epitope variants were further analysed for 
their TCR Vβ chain usage on CD8+IFN-γ+ T cells via flow cytometry. One example from each 
subgroup is shown (A-D). 
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4.4.4 HLA-B*57-restricted epitope NS5B2629 
As a last example, an HLA-B*57-restricted epitopes situated at position NS5B2629 
was analysed. The detected CD8+ T cell responses were mainly directed against 
GT1a (6 out of 10 patients; figure 4.20). In four patients a GT1b-specific response 
could be detected in addition to the GT1a response, while three patients also had 
GT3a-specific responses. 
The GT1b responses were always to some extend cross-reactive with the GT1a 
epitope and vice versa, but no cross-reactivity could be detected between the GT3a-
specific responses and the GT1 epitopes in two of the patients (PWID370 and 
PWID376). Only PWID114 showed minimal cross-reactivity between all of the tested 
genotype-specific epitopes. 
 
Figure 4.20: CD8+ T cell response against the HLA-B*57-restricted epitope NS5B2629 
The relative frequency of CD8+IFN-γ+ T cells after 10 days of in vitro expansion in the presence of the 
HLA-B*57-restricted peptide NS5B2629 was examined in 10 HLA-B*57 positive, HCV seropositive 
PWID via ICS and flow cytometric analysis. Cross-reactivity of CD8+ T cells was evaluated by ICS for 
IFN-γ after restimulation with either the GT1a, GT1b or GT3a peptide. Each bar represents the CD8+ T 
cell response to one peptide. 
 
To determine whether the GT1a- and GT3a-specific CD8+ T cell responses constitute 
two distinct T cell populations, the Vβ repertoire of these cells was analysed. As can 
be seen in figure 4.21, there is no overlap in the Vβ chains present on the surface of 
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GT1a- and GT3a-specific cells in either patient. The Vβ chain usage also differed 
between the two patients, although Vβ7.2 and Vβ22 were present on the surface of 
GT1a-specific cells in both patients. 
 
Figure 4.21: Vβ repertoire of HLA-B*57 NS5B2629-specific CD8+ T cells 
PWID with positive IFN-γ responses against both GT1a and GT3a were further analysed for their TCR 
Vβ chain usage via flow cytometry. Vβ repertoire of PWID370 (A) and PWID376 (B) are shown for 
KSKKTPMGF (GT1a)-specific CD8+ T cells and TSKKTPLGF (GT3a)-specific CD8+ T cells. 
 
In summary, not cross-reactive responses against two GT-specific variants were 
found for 4 out of 5 tested epitopes, while one epitope was cross-reactive between all 
tested GT variants (NS5B2841).  TCR Vβ chain analysis confirmed, that in most cases 
distinct CD8+ T cell population were activated by the genotype-specific variants. 
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When the responses against all tested epitopes are summarised (figure 4.22), no 
significant differences in the recognition of the tested epitopes could be detected 
between the different PWID subgroups, although there was a slight trend towards 
more responses against both genotypes in GT3 infected and RNA negative PWID 
compared to GT1 infected PWID.  
 
 
Figure 4.22: PWID with CD8+ T cell responses against different variants of the same 
epitope 
The number of responses against both genotypes from the ICS data for all 5 tested epitopes were 
added together and the percentage of total tested PWID within each subgroup (GT1 infected, GT3 
infected or RNA neg) was calculated. Statistical significance was tested using Fisher’s exact test. 
 
 
Overall, we could show that priming against two different GT-specific variants of the 
same epitope is possible within one patient for most epitopes, even though these 
responses are not more frequently observed in PWID with resolved infection. 
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4.5 Depletion of HCV-specific CD8+ T cells 
Another factor influencing the outcome of HCV infection is exhaustion or outright 
depletion of HCV-specific CD8+ T cells. To investigate if HCV-specific cells are in any 
way deleted in chronically infected patients, we first looked at the frequency of these 
cells directly after thawing and after 7 days of peptide-specific expansion via MHC 
class I dextramer staining (figure 4.23) in a preselected group with known responses 
against immunodominant CD8+ T cell epitopes. 
On day 0 HCV-specific cells were significantly less frequent in chronically infected 
patients compared to patients with resolved infection (p=0.0233, figure 4.23A). When 
the chronic subgroup was further subdivided into GT1a and GT3a infected patients, 
the GT1a infected subjects had even lower frequencies of HCV-specific cells, while 
GT3a infected patients displayed a frequency that was relatively close to patients 
with resolved infection. This difference in frequency between the genotypes can 
probably be explained by the fact, that the tested dextramer sequences were 
predominantly GT1-specific, (5 out of 7, see table 2.3). Consequently, the majority of 
responses detected in GT3a infected patients were probably due to a previously 
resolved GT1a infection. On day 7 after peptide specific expansion, no differences in 
the frequencies of HCV-specific cells could be detected between the three subgroups 
(figure 4.23B). 
 
 
Figure 4.23: Frequency of HCV-specific CD8+ T cells 
The frequency of HCV-specific CD8+ T cells was determined via MHC class I dextramer staining 
directly after thawing (A) and after 7 days of peptide specific expansion (B). p-values were calculated 
using Mann-Whitney test. 
 
Next we wanted to check whether the autologous viral sequence matched the 
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the chronically infected patients were determined (table 4.7). Except for one case, 
the viral sequence did not match the dextramer sequence.  
 
Table 4.7 Cross-reactivity between autologous viral sequence and peptide sequence 
ID infecting genotype peptide sequence 
autologous viral 
sequence cross-reactivity 
PWID153 1a ALYDVVTKL ALYDVVSKL yes 
PWID153 1a GVDPNIRTGV GVEPNIRTGV no 
PWID160 1a CINGVCWTV CINGVCWSI no 
PWID160 1a ALYDVVTKL ALYDVVGKL no 
PWID174 3a ATDALMTGY ATDALMTGF no* 
PWID187 1a ATDALMTGY ATDALMTGF no* 
PWID197 3a KLVALGINAV KLAGMGLNAV no 
PWID197 3a CINGVCWTV TVGGVMWTV no 
PWID204 1a ARMILMTHF VRMILLTHF no* 
PWID206 3a IPFYGKAI IPFYGKAL no 
PWID274 3a IPFYGKAI VPFYGKAI partial 
PWID280 1a CINGVCWTV CINGVCWTV - 
PWID280 1a KLVALGINAV KLVALGVNAV n.d. 
PWID299 1a KLVALGINAV KLVTLGINAV no 
PWID347 3a ATDALMTGY ATDALMTGF no* 
*cross-reactivity was not tested for this patient, but similar studies have been published previously 
(Dazert et al., 2009; Neumann-Haefelin et al., 2008a); amino acids that differ between the dextramer 
sequence and the autologous viral sequence are marked in red; n.d.: not done. 
 
As a next step the cross-reactivity between the autologous viral sequence and the 
dextramer sequence was determined via ICS to investigate if these substitutions 
constitute escape mutations. Only one case of full cross-reactivity and one case of 
partial cross-reactivity were found. In all other cases no cross-reactivity between the 
autologous viral sequence and the dextramer sequence could be detected indicating 
that the viral sequence could no longer be recognised and that these substitutions 
therefore constitute viral escape mutations.  
As the presence of escape mutation in nearly all targeted epitopes with detectable 
responses does not adequately explain the differences in the frequencies of HCV-
specific cells between GT1a and GT3a, we wanted to determine whether the 
depletion of HCV-specific cells in chronic PWID could be due to premature apoptosis 
of these cells. For this purpose the expression of the pro-apoptotic marker Bim was 
examined on these HCV-specific CD8+ T cells directly after thawing and after 7 days 
of expansion (figure 4.24A and B). Bim has been previously shown to be upregulated 
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on hepatitis B virus (HBV)-specific CD8+ T cells, probably caused by their antigen-
specific activation in the liver compartment (Lopes et al., 2008).  
 
 
Figure 4.24: Expression of Bim and CD38 on HCV-specific CD8+ T cells 
The expression of Bim and CD38 on HCV-specific CD8+ T cells was determined via flow cytometry. 
Median florescence intensity (MFI) ratios of Bim (A, B and E) and CD38 (C, D and F) expression was 
calculated by dividing the MFI value of the HCV-specific CD8+ T cell population by the MFI value of 
the remaining CD8+ T cell population. Horizontal lines indicate the mean. p-values were calculated 
using Student’s t test (*:p>0.05, **: p>0.01 ***: p>0.001). 
 
However, no differences in the expression of Bim was observed on HCV-specific 
CD8+ T cells at day 0 or day 7 between chronically HCV infected PWID and HCV-
RNA negative PWID (figure 4.24A and B). Moreover, there was also no difference in 
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Bim expression between HCV-specific CD8+ T cells and CMV- or Flu-specific CD8+ T 
cells. Even in the few cases where continuous antigen stimulation was expected 
based on the cross-reactivity profiles of the autologous epitope sequences, there 
were still no significant differences in Bim expression. Similar Bim levels were 
observed in CD8+ T cells that did not recognise the autologous viral sequence 
(shown in black in figure 4.24) and in those with full or partial recognition (shown in 
gray or white). Of note, the single patient harbouring a virus with the prototype 
sequence in the targeted epitope also did not show differential Bim expression 
(shown in red). Upon antigen-stimulation Bim expression significantly increased by 
day 7 (figure 4.24E). The same results were observed for the activation marker CD38 
(figure 4.24F). These findings indicate, that not only CD38 but also Bim is 
upregulated upon activation of CD8+ T cells. Taken together, we do not find evidence 
that Bim is upregulated on HCV-specific CD8+ T cells during chronic infection in 
PWID.  
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5 Discussion 
PWID are the main risk group for acquiring HCV infection in Germany and other 
developed countries (Aceijas and Rhodes, 2007; Cornberg et al., 2011; Nelson et al., 
2011). Due to their frequent risk behaviour of sharing needles and other injection 
equipment, they are likely to be repeatedly exposed to HCV. In our cohort from 
Essen GT1 and GT3 are the predominant genotypes and the distribution of 
genotypes is similar to those reported in other PWIDs in Germany (Zimmermann, 
2012). Exposure to both genotypes is therefore highly probable for these patients. In 
this study we wanted to investigate the influence of the infecting viral genotype on the 
antiviral immune response with a particular focus on CD8+ T cells. 
 
5.1 Genetic host factors 
5.1.1 IFNL3 genotype 
The C/C genotype of the SNP rs12979860 upstream of the IFNL3 gene was first 
identified in a genome wide association study and was strongly associated with 
spontaneous clearance of HCV infection and enhanced response to treatment (Ge et 
al., 2009; Thomas et al., 2009). A role for this genetic marker in clearance of HCV 
could also be confirmed in other studies of cohorts that were mainly infected with 
GT1 (Beinhardt et al., 2012; Rauch et al., 2010; Tillmann et al., 2010), while the 
IFNL3 genotype was found to only play a minor role in viral clearance in cohorts 
infected with GT2 or GT3 (reviewed in (Lange and Zeuzem, 2011)). This was in line 
with our data, as an increased frequency of the protective C/C genotype was only 
observed in patients with resolved HCV infection when compared to GT1 infected 
patients. The difference was far less pronounced when compared to GT3 infected 
patients.  
It has been shown that the SNPs near this gene locus affect the expression of IFNL3, 
with the rs12979860 C/C genotype resulting in higher expression of IFNL3 within the 
liver compared to the T/T genotype (Dill et al., 2011), but the precise mechanism 
behind the protective effect has not been elucidated yet. The protective C/C 
genotype has also been linked to symptomatic hepatitis and jaundice, thereby 
indicating increased cytotoxic activity in the liver that might be caused by CD8+ T 
cells. In addition, it has been previously described that IFNL3 could augment CD8+ T 
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cell cytotoxicity and memory responses in macaques vaccinated with HIV antigen 
(Morrow et al., 2010) as well as enhance the adaptive immune response after 
vaccination in mice (Morrow et al., 2009). One small study of 53 Italian patients has 
even found a correlation between stronger and broader cell-mediated immunity and 
the rs12979860 C/C genotype, but no differentiation between CD4+ and CD8+ T cells 
was implemented (Spada et al., 2013).  
We first analysed the CD8+ T cell response in 115 PWID with HLA-matched optimal 
peptides. In line with other cross-sectional studies, PWID with resolved HCV infection 
had a significantly greater magnitude of the CD8+ T cell response compared to PWID 
with chronic infection (Giugliano et al., 2009; Lauer et al., 2004), while the breadth of 
the response was also increased, but did not reach significant levels. In this study the 
percentage of recognised epitopes out of all tested epitopes was used as an indicator 
for the breadth of the response. Although this approach does not allow insights into 
the full epitope repertoire, it can still be used to estimate to what degree the 
“potential“ repertoire of known CD8+ T cell responses was utilised within each 
patient. Interestingly, there was no difference in the CD8+ T cell response between 
GT1 and GT3 infected patients, even though the tested epitopes corresponded 
mostly to the GT1 sequence and sequence differences are known to prevent cross-
recognition of most epitopes (Giugliano et al., 2009). The majority of the detected 
responses in GT3 infected PWID therefore probably stem from memory responses 
from a previously resolved GT1 infection. 
To test the hypothesis that the IFNL3 genotype influences the magnitude of the CD8+ 
T cell response, this data set was stratified for the IFNL3 genotype to determine a 
possible influence on the CD8+ T cell response. However, no differences in either the 
magnitude or the breadth of the CD8+ T cell response could be detected between 
patients with the C/C and non-C/C genotypes indicating that the CD8+ T cell 
response was independent of the IFNL3 genotype.  
One possible limitation of the study is its cross-sectional design. In longitudinal 
studies in patients with acute HCV infection it has been shown that the magnitude of 
the CD8+ T cell response does not differ between patients with spontaneous control 
of HCV replication and those that go on to develop chronic HCV infection suggesting 
that functional differences in HCV-specific T cells may be important during the acute 
phase (Cox et al., 2005a). Whether IFNL3 might still influence these functional 
differences has to be determined in longitudinal studies in larger cohorts. 
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5.1.2 HLA class I alleles 
The HLA class I locus is the most polymorphic gene in the entire human genome 
(Goulder and Walker, 2012; Robinson et al., 2011) and the products of this gene 
locus, HLA-A, HLA-B and HLA-C molecules, have been shown to be associated with 
differential outcome of HCV infection in several studies. As CD8+ T cell responses 
are important for viral clearance (Bowen and Walker, 2005) and HLA molecules 
determine which epitope can be presented to CD8+ T cells in order to elicit a 
response, this association is not surprising. In particular, HLA-A*03, HLA-B*27, 
HLA-B*57 and HLA-C*01 have been associated with viral clearance (Kim et al., 
2011; Kuniholm et al., 2010; McKiernan et al., 2004), while HLA-B*08, HLA-B*18 and 
HLA-C*04 have been linked to persistent infection (Kim et al., 2011; McKiernan et al., 
2004; Thio et al., 2002).  
Nevertheless, the data on which HLA class I alleles are associated with HCV 
infection outcome is still conflicted, because different studies found different HLA 
alleles to be associated with viral clearance. These differences can probably be 
attributed to differences in study populations as well as study design. For example, 
the studies by Thio et al., Kim et al. and Kuniholm et al. all analysed multiracial 
cohorts and did not differentiate between different HCV genotypes, while the study by 
McKiernan et al. focused on a single-source GT1b outbreak in Irish women. 
Interestingly, another study of a similar single-source GT1b outbreak in German 
women found none of the associations between HLA alleles and infection outcome 
that were reported in the Irish cohort (Ziegler et al., 2013). The different findings in 
these two studies have been attributed to substitutions in immunodominant CD8+ T 
cell epitopes in the German cohort. These findings show that sequence differences in 
immunodominant epitopes of the infecting virus can influence the outcome of HCV 
infection. Consequently, we wanted to test what influence different genotypes (GT1 
and GT3 in particular) have on the association of certain HLA alleles with HCV 
infection outcome. 
Our cohort consisted of 310 PWID from Essen. Even though the race/ethnicity of 
participating patients was not explicitly investigated, a Caucasian HLA background 
can be assumed for the majority of PWID, which is supported by the fact that the 
distribution of HLA alleles did not significantly differ between our study cohort and the 
general German population. The analysis of associations between HLA class I alleles 
and outcome of HCV infection in our PWID cohort only revealed two significant 
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results: HLA-B*08 was significantly more common in GT1 infected patients, but not in 
GT3 infected patients, compared to patients with resolved infection, while HLA-B*27 
was significantly more frequent in patients with resolved infection compared to both 
GT1 and GT3 infected patients. Both observations are interesting in different ways. 
The HLA-B*08 association with viral persistence in GT1, but not GT3 shows that 
differences in the viral genotype can influence infection outcome. HLA-B*08 has also 
been associated with more rapid disease progression or increased susceptibility to 
infection in HIV (Carlson et al., 2012; Goulder and Walker, 2012; Pereyra et al., 
2010; Steel et al., 1988) as well as a detrimental outcome during HCV infection in 
other studies that either included only GT1 infected patients (McKiernan et al., 2004) 
or a majority of GT1 infected patients (Kim et al., 2011), even though one study also 
reported it as a protective allele (Hraber et al., 2007). The results from this last study 
might be less reliable, as no information on the infecting viral genotype was available 
and chronically infected patients could only be distinguished from patients with 
resolved infection in a small minority of patients due to insufficient data. The 
mechanism behind this detrimental effect has not been studied yet, but a similar 
detrimental effect has been shown in HIV. The association of HLA-B*35:01 with rapid 
disease progression in B clade HIV infection has been linked to the absence of the 
immunodominant CD8+ T cell epitope Gag253-262, while no disease susceptibility has 
been found for C clade infection where this epitope is highly targeted even though 
the sequences between clades only differ in one amino acid residue (Gao et al., 
2001; Lazaryan et al., 2011; Pereyra et al., 2010). 
Finding a CD8+ T cell epitope that could explain the detrimental effect of HLA-B*08 
during HCV GT1 infection would require more extensive screening of CD8+ T cell 
responses in GT3, because the known immunodominant HLA-B*08 epitope in GT1 
(NS31395 HSKKKCDEL) has been shown to be cross-reactive with the corresponding 
GT3 epitope (NS31395 HSKKKCDEI) (Giugliano et al., 2009). Data on other CD8+ T 
cell epitopes in GT3 is sparse, as only two studies to date have analysed the CD8+ T 
cell response during GT3 infection: one study from our own lab that focused on 
responses against the NS3 protein and only found the before mentioned epitope 
(Giugliano et al., 2009) and a study by Humphreys et al. that did not narrow down the 
HLA-restriction for new epitopes in GT3 (Humphreys et al., 2012).    
A protective effect of HLA-B*27 has been previously described for HIV (Goulder and 
Watkins, 2008; Kaslow et al., 1996; McNeil et al., 1996; Pereyra et al., 2010; 
Discussion 
 
 86 
Trachtenberg et al., 2003) and for GT1b of HCV (McKiernan et al., 2004), but a 
second study by Neumann-Haefelin et al. concluded that this protective effect was 
limited to GT1 and would not be valid in GT3, because the immunodominant GT1 
epitope NS5B2841 ARMILMTHF, which was linked to the protective effect, is neither 
conserved nor effectively targeted in GT3 (Neumann-Haefelin et al., 2010). In 
addition, they also found HLA-B*27 to be significantly more frequent in GT3 infected 
patients compared to GT1 infected patients. This comparison is different from the 
one analysed in this project, as we mainly compared HLA allele frequencies between 
patients infected with either genotype to patients with spontaneously resolved 
infection, while any data on patients with resolved infection is missing in the other 
study. Consequently, conclusions with regard to the “protectiveness” of HLA-B*27 
are limited when patients with spontaneous resolution of HCV-RNA were excluded 
from the analysis. The comparison of the frequency of HLA-B*27 between the two 
genotypes does not yield significant differences for genotype or phenotype 
frequencies in our cohort (p=0.7793 and p=0.7758, respectively; Fisher’s exact test), 
even though very similar numbers of GT3 infected patients were included. The exact 
reasons for different results in the cohort from Freiburg and our cohort are unknown. 
One striking difference is that our cohort was exclusively comprised of PWID 
whereas the cohort from Freiburg included anti-HCV positive patients irrespective of 
the transmission route. Repetitive exposures to HCV as observed in PWID may be 
required for the protective effect of HLA-B*27 against HCV GT3 infection, however, 
this needs to be further addressed.  
 
5.2 HLA-B*27-restricted HCV-specific CD8+ T cell responses in GT3a 
The known immunodominant epitope NS5B2841 in GT1 has been shown not to be 
targeted in chronically GT3 infected patients by Neumann-Haefelin et al. (Neumann-
Haefelin et al., 2010). Nevertheless, we were able to detect CD8+ T cell responses 
against the GT3 sequence of nearly equal or even greater magnitude in four patients. 
This was exclusively in patients that showed evidence for a resolved GT3 infection in 
the form of other CD8+ T cell responses that are only immunogenic in GT3a or not 
cross-reactive with GT1 or were chronically infected with GT3. The difference 
between our results and those described in the previous study can likely be 
explained by the inclusion of patients with resolved infection that have previously 
been infected with GT3, as CD8+ T cell responses against this genotype would be 
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easier to detect in such patients. In the future a closer examination of these 
NS5B2841-specific cells that are fully cross-reactive between GT1 and GT3 would be 
interesting, in particular with regard to their TCR sequence to see whether 
differences can be found between cells that do recognise the GT3 sequence and 
those that do not. 
Overall the responses to the GT3 variant of the NS5B2841 probably cannot explain the 
protective effect of HLA-B*27 we observed in our cohort, as strong responses only 
occurred in a small minority of patients. Therefore, we wanted to see whether we 
could identify novel CD8+ T cell epitopes directed against GT3 that might not be 
immunogenic in GT1 due to the sequence differences between GT1 and GT3. A 
screen of predicted HLA-B*27:05 binding epitopes in GT3 after in vitro expansion 
revealed two novel vigorously targeted epitopes in NS2 (NS2840 and NS2942). These 
were confirmed to be strong binders in a binding assay involving UV-induced 
peptide-exchange reactions. Surprisingly, this assay also showed that only one third 
(18 out of 54 tested peptides) of predicted and known epitopes actually bound with 
high affinity to HLA-B*27:05 in an experimental setting indicating that computational 
models should not be used as the sole indicator for peptide-MHC binding affinity. 
High affinity binding to HLA-B*27:05 could be shown for nearly all peptides that 
elicited a response during our ICS screen, which is not surprising as a strong 
peptide-MHC binding is necessary to create an interaction with the TCR on the CD8+ 
T cell.  
Only the previously described epitope p7780 had a low binding affinity to 
HLA-B*27:05. This epitope has only been described in a screen of one acutely 
infected patient (Neumann-Haefelin et al., 2006). This patient was of Sicilian ancestry 
and was later shown to carry not the most common HLA-B*27 subtype HLA-B*27:05, 
but the less frequent HLA-B*27:02 allele (Nitschke et al., 2014). Another epitope 
identified in this patient, NS5B2820, has already been shown to be restricted by 
HLA-B*27:02 and not HLA-B*27:05. The same likely applies to the p7780 epitope and 
would thereby explain the low binding affinity to HLA-B*27:05.  
The two novel GT3 epitopes NS2840 and NS2942 were also confirmed to be vigorously 
targeted ex vivo via MHC class I dextramer stainings. Especially for the NS2942 
epitope the frequency of detection of specific CD8+ T cells was nearly as high as for 
the known immunodominant GT1 epitope NS5B2841 and the magnitude of the 
response was comparable as well. In addition, the NS2942 epitope was targeted in the 
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majority of GT3 infected patients and patients with resolved infection. The NS2840 
epitope seemed to be subdominant, as it was targeted with reduced magnitude and 
in fewer patients compared to the NS5B2841 and NS2940 epitope. 
When the CD8+ T cell response against the GT1a and GT1b variants of the two NS2 
epitopes were tested, no responses against the GT1 sequences were detected and 
no cross-reactivity between the GT3-specific responses and either of the GT1 
variants could be detected, indicating that both novel epitopes are only immunogenic 
in GT3a, but not in GT1a or GT1b. This can probably be attributed to the fact that the 
HLA-B*27:05 binding anchor arginine at positions 2 of the epitope is not conserved in 
the majority of GT1 sequences. 
No differences in the frequency of sequence polymorphisms could be observed in the 
subdominant NS2840 epitope between GT3 infected patients according to their HLA-
B*27 status. Additionally, the prototype sequence and the viral variants were all 
cross-reactive to some degree and responses against the viral variants could be 
detected in PWID with resolved infection.  
In contrast to this, the biological relevance of the CD8+ T cell response directed 
against the dominant NS2942 epitope was further corroborated by the fact that 
sequence polymorphisms in this epitope in chronically GT3a infected patients were 
more likely to occur in HLA-B*27 positive patients than in HLA-B*27 negative 
patients. Furthermore, functional analysis revealed no CD8+ T cell responses against 
the viral variants in the GT3a infected PWID harbouring the respective variant and no 
cross-reactivity between the prototype sequence and the viral variants could be 
detected in PWID with a response against the prototype sequence. Taken together 
our data indicate that HLA-B*27-mediated selection pressure on the NS2942 epitope 
associated with viral escape occurs in GT3a infected patients. This is again similar to 
the observations made for the NS5B2841 epitope in GT1, for which sequence 
differences between the prototype and the autologous viral sequence were also 
frequently found in HLA-B*27 positive patients, while the sequence was mostly intact 
in HLA-B*27 negative patients (Neumann-Haefelin et al., 2006). For this epitope the 
protective effect of HLA-B*27 has been attributed to the fact that several mutations 
inside this epitope are necessary to achieve viral escape, as CD8+ T cells specific for 
the prototype sequence are otherwise able to cross-recognise the viral variants 
(Dazert et al., 2009), representing a relatively high genetic barrier to escape. This 
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mechanism of protection does probably not apply for the NS2942 epitope, as one 
mutation was enough to abrogate recognition of the epitope by CD8+ T cells.  
Severe impairment of viral fitness by escape mutations have also been associated 
with the protective effect of two other HLA class I alleles: HLA-A*03 and HLA-B*57. 
In both cases secondary compensatory mutations were selected in patients carrying 
the respective allele as the primary escape mutations incurred high viral fitness costs 
(Fitzmaurice et al., 2011; Oniangue-Ndza et al., 2011). Unfortunately, similar 
experiments cannot be performed for GT3a at the moment, as no full-length 
replication model for HCV GT3a is available yet.  
 
5.3 T cell responses targeting different variants of the same epitope 
Due to sequence differences between the different HCV genotypes, CD8+ T cell 
responses directed against a specific epitope are not necessarily cross-reactive. In a 
previous study from our group the co-existence of two distinct CD8+ T cell 
populations directed against the both the GT1 and the GT3 sequence of the 
HLA-B*13 restricted epitope NS31627 that were not cross-reactive could be shown 
(Giugliano et al., 2009). In addition, responses against both genotype 1 and genotype 
3 were more frequently observed in PWID with resolved infection, when both cross-
reactive and distinct responses were considered together. 
A similar effect has been observed during HIV infection, as an expansion of a CD8+ T 
cell response against a related, but not cross-reactive variant epitope can occur after 
viral escape mutation in the corresponding CD8+ T cell epitope (Allen et al., 2005; 
Roider et al., 2013). This ability to mount de novo responses to a variant epitope 
have been mainly described for CD8+ T cell responses restricted by HLA alleles 
associated with a protective effect during HIV infection, e.g. HLA-B*27 and HLA-B*57 
(Bailey et al., 2006; Feeney et al., 2005; Ladell et al., 2013; O’Connell et al., 2011). 
Here we wanted to determine whether the co-existence of distinct CD8+ T cell 
populations against both GT1 and GT3 restricted by HLA alleles that are associated 
with protection during either HIV or HCV infection (HLA-B*13, HLA-B*15, HLA-B*27 
and HLA-B*57) occurs in PWID exposed to both genotypes. We tested 5 known 
immunodominant epitopes that differed in at least two amino acid positions between 
the GT1a or GT1b sequence and the GT3a sequence for the IFN-γ response of the 
CD8+ T cells against the genotype-specific sequences as well as the cross-reactivity 
between all variant epitopes. CD8+ T cell responses against GT1 and GT3 were 
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found in all 5 tested cases. In 4 cases these represented two distinct, not cross-
reactive responses, while the responses against the HLA-B*27-restricted epitope 
NS5B2841 were at least partially cross-reactive between the different genotypes.  
When the responses against these epitopes were considered collectively, no 
evidence of a protective effect of the CD8+ T cell responses targeting variants of the 
same epitope within one patient could be found, as there was no significant 
difference in the frequency between patients with chronic and resolved HCV 
infection. 
Whether priming against two variants of the same epitope is possible has not been 
previously conclusively shown for HCV. Studies so far have only investigated 
whether CD8+ T cells against escape variants can be primed during ongoing 
infection, but only sparse evidence for such populations was found (Salloum et al., 
2008; Uebelhoer et al., 2008). In murine models it has been shown that secondary 
responses against distinct but closely related epitopes are impaired, a concept 
termed original antigenic sin (Klenerman and Zinkernagel, 1998), even though this is 
not a universal concept with regard to CD8+ T cells (Zehn et al., 2010). 
Here we show that priming of two distinct genotype-specific variants is possible for 
the majority of tested epitopes. The existence of these cells has important 
implications for vaccine design. If priming against two different variants of the same 
epitopes is possible within one patient, both could be included in a future vaccine 
thereby making it efficacious against several genotypes without having to rely on 
epitopes that are conserved between the different genotypes. 
 
5.4 Depletion of HCV-specific CD8+ T cells 
CD8+ T cell are known to play an important role in spontaneous clearance of acute 
HCV infection in both chimpanzee studies (Thimme et al., 2002) and humans 
(Thimme et al., 2001) as shown by the temporal association of their appearance with 
resolution of infection. Furthermore, during in vivo depletion experiments in 
chimpanzees, CD8+ T cells have been shown to be the key effector cells controlling 
HCV replication (Shoukry et al., 2003). Exhaustion of these cells has been frequently 
observed in patients with chronic infection (Nakamoto et al., 2009; Radziewicz et al., 
2007, 2008; Spangenberg et al., 2005; Wedemeyer et al., 2002) and exhausted 
CD8+ T cells have been shown to be more prone to apoptosis linked to an 
upregulation of PD-1 expression (Radziewicz et al., 2007). In addition, decreased 
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frequencies of HCV-specific CD8+ T cells have been frequently observed in 
chronically HCV infected individuals compared to patients who spontaneously 
resolve infection (Lauer et al., 2004), further indicating that apoptotic deletion of 
HCV-specific CD8+ T cells might play a role in determining HCV infection outcome.  
We analysed the ex vivo frequency of HCV-specific CD8+ T cells in patients with 
either chronic or resolved infection via MHC class I dextramer stainings and found 
significantly lower frequencies in chronic patients compared to patients with resolved 
infection even though only patients with known responses against the tested epitopes 
were selected for analysis. A slight trend towards a lower frequency of HCV-specific 
CD8+ T cells in GT1 infected patients compared to GT3 infected patients was 
observed, but did not reach statistical significance. 
One possible explanation for the lower frequency of HCV-specific CD8+ T cells in 
chronic patients is apoptotic deletion of this cell population. A possible mediator of 
apoptosis is the proapoptotic molecule Bim. This Bcl-2 family member is important for 
the regulation of T cell homeostasis, as it plays a central role in the initiation of 
apoptosis signalling in lymphocytes (Bouillet et al., 1999; O’Connor et al., 1998). In 
this context Bim is on the one hand important for the shutdown of CD8+ T cell 
responses after acute viral infections to limit tissue damage (Pellegrini et al., 2003), 
while on the other hand downregulation of Bim is necessary to allow CD8+ T cell 
memory formation (Sabbagh et al., 2006). In addition, Bim has been implicated with 
induction of apoptosis in CD8+ T cells that have been activated in the liver in murine 
models (Holz et al., 2008). Bim has also been found to be upregulated in HBV-
specific CD8+ T cells from chronic HBV patients, which was again linked to their 
intrahepatic antigen-specific activation (Lopes et al., 2008). As the activation of HCV-
specific CD8+ T cells would also occur in the liver compartment, an involvement of 
Bim seems likely. 
Bim expression has also previously been investigated in HCV-specific CD8+ T cells 
(Larrubia et al., 2011, 2013), but no differences in Bim expression levels have been 
found in PBMC from patients with either chronic or spontaneously resolved HCV 
infection directly ex vivo. As both studies by Larrubia et al. were limited to two HLA-
A*02 restricted epitopes in GT1 infected patients and did not take the influence of the 
autologous viral sequence on the exhaustion status of the CD8+ T cells in chronic 
patients into account, we analysed the Bim expression in HCV-specific CD8+ T cells 
from patients infected with either GT1 or GT3 using MHC class I dextramer restricted 
Discussion 
 
 92 
by multiple HLA alleles. We could not find differential expression of Bim between 
patients with chronic and persistent HCV infection either. This effect might partially 
be explained by the fact that escape mutations were present in nearly all studied 
epitopes from chronically infected PWID, but Bim expression levels were not 
elevated when partial or full cross-reactivity with the autologous viral sequence could 
be shown or when the viral sequence matched the tested epitope sequence, either.  
Another factor influencing our observation of lack of Bim involvement might be the 
fact that HCV-specific CD8+ T cells in general (Neumann-Haefelin et al., 2008b) and 
those prone to apoptosis in particular (Radziewicz et al., 2008) have been shown to 
be more frequent in the liver compared to the peripheral blood. Consequently, Bim 
levels in HCV-specific CD8+ T cells in the peripheral blood might differ from those 
sequestered in the liver. A comparison between HCV-specific CD8+ T cells between 
both compartments would be interesting and necessary to exclude this possibility. 
Unfortunately, acquiring samples for this analysis is going to be difficult, as liver 
biopsy samples are not as easily obtained as blood samples and ethical concerns 
preclude such a procedure in patients with resolved HCV infection because there is 
usually no medical indication. 
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6 Summary 
Transmission of hepatitis C virus (HCV) is closely linked to blood-blood contact. 
Accordingly, in developed countries HCV is mainly acquired by people who inject 
drugs (PWID). Importantly, PWID living in Germany are frequently exposed to 
different HCV genotypes (GTs) with GT1 and GT3 being predominant. As the 
infecting genotype can influence the infection outcome and HCV-specific CD8+ T 
cells play a major role in the immune response against HCV, we wanted to 
investigate the influence of the viral GT on the antiviral CD8+ T cell response in more 
detail in highly exposed individuals. For this purpose we worked with a cohort of 363 
PWID from Essen, Germany that consisted of patients that remained seronegative 
for HCV (11%), patients with spontaneously resolved HCV infection (25%) and 
chronically infected patients (33% GT1, 27% GT3 and 4% other GTs). 
As a first step, we examined two host genetic factors that have been implicated with 
affecting HCV infection outcome. Single nucleotide polymorphisms near the IFNL3 
gene have been associated with spontaneous clearance and enhanced response to 
therapy. In our cohort the “protective” IFNL3 rs12979860 C/C GT was significantly 
less frequent in GT1 infected patients compared to patients with resolved HCV 
infection, while subjects infected with GT3 showed an intermediate GT frequency. No 
significant differences in the CD8+ T cell response depending on the IFNL3 GT were 
detected, suggesting that the protective effect mediated by the IFNL3 C/C GT is 
independent of the CD8+ T cell response. 
Next, the impact of the HLA class I genotype on infection outcome was determined. 
In this cohort HLA-B*08 was a risk allele for GT1 infection, whereas HLA-B*27 was 
protective against both GT1 and GT3 infection. This second finding was unexpected, 
as HLA-B*27 was so far only described to protect against GT1 due to sequence 
differences in the immunodominant CD8+ T cell epitope NS5B2841 between both 
genotypes. We therefore aimed to identify novel GT3-specific CD8+ T cell responses 
that might mediate the protective effect. By screening predicted HLA-B*27-binders 
we identified the two novel epitopes, NS2840 GRLIWWNQY and NS2942 
GRWFNTYLY, with the latter one being immunodominant in GT3. The strength of the 
CD8+ T cell response to the immunodominant GT3-specific B*27-epitope was 
comparable to the response against the known GT1-specific NS5B2841 epitope. Viral 
sequence analysis of the NS2 epitope regions provided evidence for mutational 
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escape in HLA-B*27-positive patients in the NS2942 epitope. In summary, different 
epitope repertoires could be detected in GT1 and GT3 infected patients indicating 
that different CD8+ T cell responses contribute to the protective effect of HLA-B*27. 
Genotype-specific differences in the elicited CD8+ T cell response can also play an 
important role in determining the outcome of HCV infection. Our group has previously 
shown that patients with CD8+ T cells active against both GT1 and GT3 are 
predominantly found in PWID with resolved infection. Here, we tested if distinct CD8+ 
T cell responses against different sequence variants of the same epitope can be 
activated in patients exposed to different genotypes. The analysis was focused on 
immunodominant epitopes presented by HLA class I alleles that have been described 
in the context of immune control of viral infections (HLA-B*13, HLA-B*15, HLA-B*27 
and HLA-B*57). Distinct responses against two GT-specific variants were found for 4 
out of 5 tested epitopes, while one epitope was cross-reactive between all tested GT 
variants. Analysis of the T cell receptor (TCR) Vβ chain repertoire confirmed in most 
cases that distinct CD8+ T cell populations were activated by the different variants.  
As a proof of principle, priming against two different GT-specific variants of the same 
epitope is therefore possible within one patient, suggesting that inclusion of different 
sequence variants of important epitopes in a prophylactic vaccine may be feasible. 
As a last factor influencing the outcome of HCV infection in different genotypes we 
looked at the deletion of HCV-specific CD8+ T cells, as a rapid loss of specific T cells 
is observed upon viral persistence and continuous antigen exposure. We confirmed 
lower frequencies of HCV-specific CD8+ T cells in chronically infected patients 
compared to patients with resolved infection. It was tested whether the pro-apoptotic 
protein Bim is involved in CD8+ T cell depletion in HCV, as it was reported that 
activation of T cells in the liver of mice and in human HBV infection leads to 
upregulation of Bim. In contrast to HBV, Bim was not differentially regulated in CD8+ 
T cells from patients with resolved or chronic HCV infection ex vivo. Upon antigen-
specific activation Bim and CD38 were both upregulated irrespective of the disease 
status. Taken together, our data suggest that dysregulation of Bim does not seem to 
contribute to CD8+ T cell depletion during chronic HCV infection. 
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7 Zusammenfassung 
Die Übertragung von Hepatitis C Virus (HCV) geschieht hauptsächlich über 
Blutkontakt, so dass intravenöse Drogengebraucher („people who inject drugs”, 
PWID) die Hauptrisikogruppe für HCV Infektionen in entwickelten Ländern darstellen. 
PWID in Deutschland sind häufig unterschiedlichen HCV Genotypen (GT) 
ausgesetzt, wobei GT1 und GT3 am weitesten verbreitet sind. Da der infizierende 
Genotyp den Ausgang der Infektion beeinflussen kann und HCV-spezifische CD8+ T 
Zellen eine wichtige Rolle bei der Immunantwort gegen HCV spielen, wollten wir im 
Detail untersuchen, welchen Einfluss der virale Genotyp auf die antivirale CD8+ T 
Zellantwort in hochexponierten Individuen hat. Zu diesem Zweck wurde eine Kohorte 
von 363 PWID aus Essen, Deutschland untersucht, die aus seronegativen Patienten 
(11%), Patienten mit spontan ausgeheilter HCV Infektion (25%) und Patienten mit 
chronischer Infektion (33% GT1, 27% GT3 und 4% andere GT) bestand. 
Zunächst wurden zwei genetische Wirtsfaktoren analysiert, die Auswirkungen auf 
den Ausgang einer HCV Infektion haben können. Einzelne Nukleotidpolymorphismen 
nahe dem  IFNL3 Gen wurden mit spontaner Ausheilung und besserem Ansprechen 
auf Therapie assoziiert. Verglichen mit Patienten mit ausgeheilter HCV Infektion kam 
der „protektive“ IFNL3 rs12979860 C/C GT in unserer Kohorte wesentlich weniger 
häufig in GT1 infizierten Patienten vor. Dahingegen hatten GT3 infizierte Patienten 
eine intermediäre GT Frequenz. Es wurden keine signifikanten Unterschiede in der 
CD8+ T Zellantwort abhängig vom IFNL3 GT gefunden. Dies deutet darauf hin, dass 
der protektive Effekt des IFNL3 C/C GT nicht durch die CD8+ T Zellantwort vermittelt 
wird. 
Als nächstes wurde der Einfluss des HLA Klasse I Genotypen auf den Ausgang der 
Infektion ermittelt. In unserer Kohorte war HLA-B*08 ein Risikoallel, wohingegen 
HLA-B*27 protektiv gegen sowohl GT1 als auch GT3 war. Diese zweite Beobachtung 
war unerwartet, da der protektive Effekt von HLA-B*27 bis jetzt nur für GT1 
beschrieben worden war. Dies wurde auf Sequenzunterschiede zwischen den 
Genotypen in dem immundominanten CD8+ T Zellepitop NS5B2841 zurückgeführt. 
Daher wollten wir neue GT3-spezifische CD8+ T Zellantworten identifizieren, die 
diesen protektiven Effekt erklären könnten. Das Screening von vorausgesagten HLA-
B*27 Bindern ergab zwei neue Epitope: NS2840 GRLIWWNQY and NS2942 
GRWFNTYLY. Das NS2942 Epitop war immundomiant in GT3 und die Stärke der 
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CD8+ T Zellantwort war vergleichbar mit dem bekannten GT1-spezifischen NS5B2841 
Epitop. Virale Sequenzanalysen der NS2 Epitopregionen lieferten Beweise für 
Escapemutationen im NS2942 Epitop. Zusammenfassend lässt sich sagen, dass 
verschiedene Epitoprepertoire in GT1 und GT3 infizierten Patienten vorhanden sind 
und daher verschiedene CD8+ T Zellen zu dem protektiven Effekt von HLA-B*27 
beitragen. 
Genotyp-spezifische Unterschiede in der CD8+ T Zellantwort können den Ausgang 
einer HCV Infektion erheblich beeinflussen. Unsere Arbeitsgruppe hat bereits zuvor 
gezeigt, dass Patienten mit CD8+ T Zellantworten, die gegen GT1 und GT3 gerichtet 
sind, hauptsächlich in PWID mit ausgeheilter Infektion vorkommen. Daher wollten wir 
testen, ob Patienten, die verschiedenen Genotypen ausgesetzt sind, distinkte CD8+ T 
Zellantworten gegen verschiedene Sequenzvarianten desselben Epitops besitzen. 
Die Analyse wurde auf immundominante Epitope konzentriert, die von HLA Klasse I 
Molekülen präsentiert werden, die im Zusammenhang mit Immunkontrolle von 
Virusinfektionen beschrieben wurden (HLA-B*13, HLA-B*15, HLA-B*27 und HLA-
B*57). Distinkte Antworten gegen zwei GT-spezifische Varianten wurden in 4 von 5 
Fällen gefunden, während ein Epitop kreuzreaktiv zwischen den getesteten GT 
Varianten war. Eine Analyse des T Zellrezeptor Vβ Kettenrepertoires bestätigte, dass 
verschiedene Varianten in den meisten Fällen distinkte CD8+ T Zellpopulationen 
aktivieren. Dies zeigt, dass ein Priming gegen zwei verschiedene GT-spezifische 
Varianten desselben Epitops in einem Patienten möglich ist. Daher wäre die 
Aufnahme verschiedener Sequenzvarianten wichtiger Epitope in eine 
prophylaktische Vakzine sinnvoll. 
Als letzter Faktor, der den Ausgang einer HCV Infektion beeinflussen kann, wurde 
die Deletion von HCV-spezifischen CD8+ T Zellen untersucht, da ein rapider Verlust 
von spezifischen T Zellen bei viraler Persistenz und kontinuierlicher 
Antigenaussetzung beobachtet wird. Wir konnten niedrigere Frequenzen von HCV-
spezifischen CD8+ T Zellen in chronisch infizierten PWID bestätigen. Es wurde 
untersucht, ob das pro-apoptotische Protein Bim eine Rolle bei der Deletion von 
CD8+ T Zellen während der HCV Infektion spielt, da die Aktivierung von T Zellen in 
der Leber von Mäusen und während der humanen HBV Infektion zu einer 
Hochregulierung von Bim führt. Im Gegensatz zu HBV war Bim in CD8+ T Zellen in 
chronischen HCV Patienten ex vivo nicht anders reguliert als in Patienten mit 
ausgeheilter Infektion. Nach Antigen-spezifischer Aktivierung waren sowohl Bim als 
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auch der Aktivierungsmarker CD38 unabhängig vom Infektionsausgang 
hochreguliert. Zusammengenommen weisen unsere Daten darauf hin, dass während 
einer chronischen HCV Infektion die Dysregulation von Bim nicht zur Deletion von 
HCV-spezifischen CD8+ T Zellen beiträgt. 
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